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 In the classic paradigm of pharmacology, small molecules bind to and modulate 
dysfunctional or overactive proteins. However, in cases where a protein is missing, this strategy 
is no longer viable. Disorders of iron metabolism are the most prevalent genetic diseases 
worldwide and currently, there are more than 25 different human hereditary diseases associated 
with loss of iron transporter function and therefore aberrant iron transport, homeostasis and/or 
metabolism. Given all of the advantageous features that make small molecules effective 
therapeutics, we questioned whether small molecules could autonomously replicate the functions 
of deficient iron-transporting proteins and thereby restore physiology in human disease relevant 
models. As the remaining endogenous networks of transporters and regulators in the cell remain 
active, we hypothesized that a build-up of labile iron would occur upstream of membranes 
missing a protein transporter. We therefore hypothesized that a small molecule mimic may be 
able to restore physiology by facilitating the movement of iron in a site- and direction-selective 
manner down the established gradient. In this vein, we discovered that a small molecule natural 
product from the bark of Cypress trees, hinokitiol, could leverage built-up iron gradients to 
restore the movement of iron into, within, and/or out of cells, and restore physiology to the 
system. Hinokitiol promotes the movement of iron in cells deficient in Fet3Ftr1, DMT1, Mfrn1, 
or FPN1 to restore growth in Fet3Ftr1 yeast, transepithelial iron transport across DMT1-deficient 
gut epithelia, hemoglobinization in DMT1- and Mfrn1-deficient erythroid progenitors, and iron 
release from FPN1-deficient gut epithelia and reticuloendothelial macrophages. To test the 
hypothesis that deficiencies of iron transporters lead to a build-up of labile iron upstream of 
protein-deficient membranes, we chose to study DMT1-deficient mouse erythroleukemia (MEL) 
cells. We observed increased endosomal iron and reduced cytosolic and mitochondrial iron in 
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DMT1-deficient MEL cells, using spatiotemporal imaging with organelle-specific, iron-sensitive 
fluorescent dyes. When treated with hinokitiol, these endosomal iron gradients were released and 
a subsequent increase in cytosolic and mitochondrial iron levels was observed. We were able to 
artificially manipulate the direction of hinokitiol mediated iron transport by first loading J774 
Mouse Macrophages with iron, adding hinokitiol and watching release of iron, followed by 
addition of a large excess of iron to the extracellular media. Upon addition of the extracellular 
iron, the direction reversed from exporting iron out of the cell to importing iron into the cell, 
further demonstrating hinokitiol’s ability to facilitate the movement of iron down an established 
gradient. We provide evidence for collaboration between hinokitiol and endogenous IRE- and 
Hif2α-mediated regulatory networks, with levels of ferritin, IRP2, TfR2, and FPN1 responding 
to changes in the dynamic iron status upon hinokitiol treatment. Administration of hinokitiol via 
oral gavage promotes gut iron absorption in DMT1-deficient Belgrade (b/b) rats and FPN1- 
deficient flatiron (ffe/+) mice. Chronic injection of hinokitiol decreases liver non-heme iron and 
increases hematocrit in flatiron mice and hinokitiol treatment also restores hemoglobinization 
and reverses anemia in DMT1- and Mfrn1-deficient zebrafish embryos. I was further able to 
demonstrate that hinokitiol at concentrations orders of magnitude higher than efficacious doses 
mainly cause loss of efficacy by sequestering intracellular iron. Thus, a small molecule restores 
site- and direction-selective iron transport in cells deficient in three distinct iron-transport 
proteins, and promotes gut iron absorption and/or peripheral hemoglobinization in corresponding 
animal models. Mechanistic studies support the role of ion gradients that build up in cases of 
missing iron transporters, enabling hinokitiol to restore site- and direction-selective 
transmembrane iron transport. Furthermore, endogenous protein-based homeostatic mechanisms 
interface with this small molecule to promote iron-related physiological processes without 
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disrupting other cellular processes. Collectively, these results suggest that small molecules that 
partially mimic the function of missing protein transporters of iron, and possibly other ions, may 
have untapped potential in the treatment of diseases resulting from a deficiency of ion 
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 In the classic paradigm of pharmacology, small molecules bind to, and modulate existing 
malfunctioning proteins; however in cases where diseases are alternatively caused by a missing 
protein this strategy is no longer viable1. Despite significant progress in other treatment strategies 
such as gene therapy, and the biosynthesis and subsequent direct replacement of missing proteins 
such as insulin, there are still many challenges associated with both treatment strategies and 
therefore many diseases caused by missing or deficient proteins remain untreatable2,3. It is clear 
that, despite the progress of medicinal research, there remains a large unmet medical need for 
new strategies to treat diseases caused by protein deficiencies. We therefore set out to find a new 
and generalizable approach to treat these currently untreatable diseases and landed on an 
interesting proposal. Due to the advantages of using small molecules as drugs, it is intriguing to 
consider the use of small molecules with protein like functions to replace missing proteins and 
thus restore physiology to protein deficient organisms.  
 Malfunctioning protein ion channels and transporters are implicated in more than 200 
diseases resulting from missing ion transporters or channels4–7. Examples include genetic 
disorders such as in cystic fibrosis, Bartter syndrome, Liddle syndrome, and microcytic anemia 
amongst others5,7,8. The Burke group has previously demonstrated the ability of amphotericin B 
(AmB), a small molecule with ion channel forming capabilities, to restore physiology in yeast 
missing TRK1 potassium transporters9.  More recently, in parallel with my thesis work other 
members of the Burke group in collaboration with the Welsh group at the University of Iowa, 
have shown that this same small molecule anion channel, AmB, can also restore bicarbonate ion 
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transport and therefore pH, viscosity, and antimicrobial peptide activity in fully differentiated, 
primary, cystic fibrosis lung epithelia as well as pH in the trachea of a pig model of cystic 
fibrosis (manuscript accepted).  I had the great and unique opportunity to work on a secondary 
project involving disorders of iron homeostasis caused by missing or deficient proteins. The 
following chapter covers the relevant background to my thesis work towards developing a small 
molecule, molecular prosthetic for the mobilization of iron and therefore the treatment of iron 
metabolic diseases.  
 
1.2 DISORDERS OF IRON HOMEOSTASIS 
 Anemia represents a major public heath problem in both developing and developed 
countries with an absolutely staggering 1.62 billion people world wide affected10. To put that 
into perspective 1.62 billion corresponds to ~25% of the worlds total population. About 50% (~1 
billion in total) cases of anemia are thought to be caused solely by iron deficiency (Iron 
Deficiency Anemia, IDA), with the highest prevalence occurring in preschool age children with 
an incidence of over 47%, and non-pregnant women which represent the group with the greatest 
number (468.4 million) of individuals affected10–12. The negative consequences associated with 
iron deficiency anemia on cognitive and physical development, and in some cases even 
mortality, in children have been well documented and represent a major cause for concern, both 
for human health as well as economic and social development in both developed and developing 
countries world wide10,13–16.  
 While iron is an essential nutrient and required for many important functions such as 
oxygen transport, electron transfer, oxidation-reduction reactions and catalytic activity in 
metaloproteins, it can also be very toxic when it builds up in excess within the body17,18. Iron is a 
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necessary nutrient because it is good at catalyzing biological reactions and is therefore often a 
cofactor in enzymes because of its redox capabilities; however, these same capabilities also lead 
to its toxicity.  When too much free iron overwhelms a biological system it can lead to Reactive 
Oxygen Species (ROS) toxicity caused by the formation of superoxide followed by the formation 
of a hydroxyl radical (OH)19–22. Hydroxyl radicals lead to DNA and protein damage as well as 
lipid peroxidation, which can cause genetic mutation, necrosis and tissue damage17,23–25.  
Therefore even though iron deficiency is a world wide problem, iron uptake, utilization, and 
storage within biological systems is highly regulated by a complex system of iron sensing 
proteins in concert with transcriptional and translational regulation17,26–31.  
Figure 1.1 Examples of disorders of iron homeostasis and the affected organs or systems. 
Disregulation of iron absorption, utilization, recycling, and excretion can affect almost every 
system of the body, resulting in many different disorders of iron homeostasis affecting almost 
every system of the body.  
Gut Disorders
Anemia of Chronic Disease, 
Iron Deficiency Anemia, 
Hereditary 
Hemochromotosis, IRIDA, 
African Iron Overload, etc.
Autoimmune Disorders
Rheumatoid Arthritis, Systemic 



















 In addition to its potential to cause toxicity, iron is at the forefront of host pathogen 
interactions32. Iron is a required nutrient for both pathogens and their hosts leading to a tug of 
war between pathogens, the microbiome and then host. This competition for resources leading to 
a molecular tug of war between pathogens, commensal microbe populations and the host; causes 
each group to balance sequestrating iron away from the other groups, while leaving enough 
labile, or free iron for their own utilization and storage32. Often, microbes biosynthesize 
siderophores to scavenge for iron in their environment, while hosts sequester iron away from 
pathogens by binding it with calprotectin in blood cells such as neutrophils, or storing it in the 
protein ferritin, or allowing it to circulate throughout the body bound  to the protein transferrin; it 
is very rare for any iron to be free of any chelation agent within the body. This strategy is utilized 
to keep pathogens at bay and to minimize the toxicity mentioned above.  
 Because of iron’s important role in biological systems, and the need for tight regulation 
of iron within the body, it makes sense that hundreds of diseases are associated with iron 
metabolism. Disorders of iron metabolism are the most common genetic deficiencies world wide 
and because iron is such an integral metal ion for many biological processes, iron overload and 
deficiency can affect almost every system and process of the body (Figure 1.1)29,33–35. Currently, 
there are more than 25 known hereditary diseases caused by deficiencies in iron regulation and 
homeostasis (Table 1.1), with additional disorders caused by acquired loss of protein function 
due to chronic illness, inflammation and other environmental factors.  
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Mendelian Disease Gene Affected Sites of aberrant iron levels 
DISEASES OF DEFECTIVE IRON ABSORPTION 
Hypochromic, 
Microcytic Anemia DMT1 
Decreased iron absorption; decreased iron in enterocytes; 
increased iron in endosomes; increased hepatic iron 
Erythropoietic 
Protoporphyria Mfrn1 
Predicted decrease of iron in mitochondrial matrix; 
predicted increase of iron in intermembrane space  
Ferroportin Disease FPN1 Increased iron in enterocytes; increased iron in Kupffer cells 
Iron Refractory Iron 
Deficiency Anemia TMPRSS6 Increased iron in enterocytes; increased iron in Kupffer cells 
Hemochromatosis DcytB Predicted decrease of iron absorption 
Wilson’s Disease ATP7B Increased iron in liver 
Menkes Disease ATP7A Increased iron in liver; increased iron deposition in the brain 
Inflammatory Bowel Disease Multiple Increased iron in enterocytes; increased iron in Kupffer cells 
Rheumatoid Arthritis HLA Increased iron in enterocytes; increased iron in Kupffer cells 
Mendelian Disease Gene Affected Sites of aberrant iron levels 
Hemochromatosos Type 1-3 HFE3, HFE2, HAMP, TfR2 
Friedreich’s Ataxia Frataxin 
Aceruloplasminemia Ceruloplasmin 
Neuroferritinopathy FTL1 
Congenital Hypochromic Anemia STEAP3 







Anemia Type I-IV 
X-Linked Sideroblastic 





FTH1-Related Iron Overload 
X-Linked Sideroblastic Anemia 
Huntington’s Disease 
Sickle Cell Disease 
Myelodysplastic Syndrome 
Hepatic Iron-Overload Insulin- 
Resistance Syndrome 

















SOD1 Iron deposition in the motor cortex of the brain 
Increased FPN1; increased iron in hepatocytes 
Increased liver and serum iron 
Increased liver and serum iron 
Increased iron in basal ganglia of brain 
Increased iron in liver, heart, pancreas, and brain 
Increased iron in liver and spleen; increased serum iron 
Increased iron absorption; increased hepatic and cardiac iron 
Increased iron in the mitochondria 
Increased iron in hepatocytes, brain, and pancreas 
Increased iron in basal ganglia of brain 
Predicted increase of endosomal iron; increased hepatic iron 
Increased iron absorption; increased hepatic iron 
Increased iron in liver and pancreas 
Increased iron in the mitochondria 
Increased iron in the mitochondria 
Increased serum iron 
Increased iron in the mitochondria 
Increased iron deposition in the brain 
Increased iron deposition in the brain 
Kufor-Rakeb Syndrome ATPC13A2 Increased iron deposition in the brain 
PLAN Disease PLA2G6 Increased iron deposition in the brain 
BPAN Disease WDR45 Increased iron deposition in the brain 
Woodhouse-Sakati Syndrome DCAF17 Increased iron deposition in the brain 
Increased serum iron; increased iron in cytoplasm 
DISEASES OF IRON-RELATED PROTEINS ASSOCIATED WITH ABERRANT TISSUE IRON LEVELS 
SECONDARY DISORDERS ASSOCIATED WITH ABERRANT TISSUE IRON LEVELS 
Table 1.1 Disorders of iron absorption, homeostasis, and metabolism. Non-inclusive list 
of hereditary diseases associated with defective iron absorption, homeostasis, and metabolism. 
metabolism. These diseases can broadly be separated into three categories: (i) Diseases of 
defective iron absorption, (ii) Diseases of iron-related proteins associated with aberrant tissue 
iron levels, and (iii) Secondary disorders associated with aberrant tissue iron levels.   
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 Unfortunately, because these disorders are caused by a deficiency of a specific protein, 
instead of an overactive or malfunctioning protein that is still physically present within the 
system, there is no protein target for a small molecule to bind to and modulate as expected in 
traditional pharmacological techniques. Therefore, many of these diseases have few treatment 
options. For example, Ferroportin Disease is caused by a dominant-negative mutation in 
ferroportin, a protein found both on the basolateral membrane of gut enterocytes as well as in 
macrophages (Figure 1.2). When ferroportin is not functioning properly patients have both 
anemia (due to lack of adequate iron absorption in the gut) as well as liver iron overload (due to 
reduced iron recycling in liver macrophages). The only treatment currently available for these 
patients is phlebotomy, or bloodletting, to reduce the liver iron burden to prevent cirrhosis. In 
some cases this leads to a worsening of the anemia they are already enduring. 
Figure 1.2 Ferroportin is important in both gut iron absorption and iron recycling in the 
liver. Ferroportin exists on the basolateral side of gut enterocytes and allows ferrous iron to 
flow into the blood where it is oxidized to ferric iron so that it can be bound by transferrin and 
circulated throughout the body. Ferroportin is also present on the cellular membrane of liver 
macrophages, called Kupffer cells, where it allows the iron released from damaged blood cells 
to be recycled and put back into circulation via transferrin.  
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1.3 IRON HOMEOSTASIS AND METABOLISM IN THE BODY 
 Iron is efficiently recycled in the body and therefore moves in a cycle (Figure 1.3). 
Typically only 1 to 1.5 mg of iron needs to be absorbed from the diet per day in order to replace 
the iron lost and keep the iron stores in the body sufficient for normal physiology36. Non-heme 
iron is absorbed from the diet by gut enterocytes through Divalent Metal Transporter 1 (DMT1, 
also known as NRAMP2, DCT1, or SLC11A2)37, and secreted into the blood by Ferroportin  
(FPN1, also known as IREG1, MTP1, or SLC40A1)38 where it is bound by transferrin29 (Figure 
1.3 A). Transferrin then circulates iron throughout the body with the vast majority of transferrin 
iron concentrating in bone marrow where reticulocytes phagocytose the transferrin, strip it of 
Figure 1.3 The Iron Cycle within the human body. A) Iron absorption by gut enterocytes, 
and iron circulation in the blood by transferrin. B) Hemoglobinization of reticulocytes causes 
C) red blood cell maturation. D) Iron recycling from damaged red blood cells by liver 







iron and then pump the iron through DMT1 into the cytosol and eventually the mitochondria39. 
Once the iron is in the intermembrane space between the outer mitochorial membrane and the 
inner membrane Mitoferrin (MFRN1, also known as SLC25A37)40,41 moves the iron into the 
mitochondrial matrix where heme synthesis occurs42,43(Figure 1.3 B). Once the 
hemoglobinization process has started the reticulocytes begin the differentiation process28,30 into 
mature red blood cells, which circulate throughout the body delivering oxygen from the lungs to 
other tissues and organs (Figure 1.3 C). When red blood cells become damaged they are 
recycled by special macrophages in the liver called Kupffer cells. Kupffer cells phagocytose the 
damaged red blood cells strip the iron from heme and secrete it into the blood stream via 
FPN144–47 (Figure 1.3 D) where transferrin once again binds it and the cycle continues (Figure 
1.3 E)48,49.  
 
1.4 THE PROSPECT OF MOLECULAR PROSTHETICS 
 The idea that an imperfect small molecule with protein-like function could mimic a 
missing protein, and allow for restoration of physiology in a diseased system, is a highly 
intriguing prospect. Small molecules have many advantages compared to other molecules such 
as oligonucleotides, proteins and peptides, which has lead them to be hugely successful as 
pharmaceuticals. This domination of the pharmaceutical industry is due to many factors 
including their naturally occurring diversity in nature and the potential to derivatize, their ease of 
delivery and bioavailability, their non-immunogenic nature, and the relative ease and cost 
effectiveness of their production and storage. That being said, proteins are large, complex 
structures that are, in most cases, highly regulated and very specialized for the specific function 
they perform. This raises the valid and logical question of how a small molecule, that is not as 
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complex, specific or specialized as the missing protein, could possibly replicate the function of 
that protein well enough in the system to allow for restoration of physiology. The answer to that 
question comes from nature itself.  
 Living systems are inherently robust, meaning that they have built in redundancy which 
allows them to adapt to environmental changes, genetic variation and injury50–54. This 
redundancy gives organisms more function than they need in order to survive so that if some of 
that function is lost they are still able to survive (Figure 1.4 Left). In fact, humans on average 
are missing about 20 proteins yet display no disease phenotype55. It is therefore, actually the 
rarer case in which a single missing or defective protein causes an organism to drop below the 




















Figure 1.4 The prospect of molecular prosthetics. The robustness of living systems 
suggests that small molecules that only partially mimic the function of missing proteins could 
be capable of restoring physiology.  
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hypothesized that a small molecule, despite being an imperfect mimic, could collaborate with the 
endogenous system and perform enough function in order to bring an organism up past that 
threshold and therefore allow for restoration of physiology to the organism (Figure 1.4 Right).  
 
1.5  MOLECULAR PROSTHETICS IN DISORDERS OF IRON HOMEOSTASIS 
 Disorders of iron homeostasis caused by missing proteins make good candidates for a 
molecular prosthetic treatment approach because the active ion pumps and passive ion channels 
upstream and downstream of the affected protein remain functional, and in some cases are even 
upregulated in order to compensate for the missing protein (Figure 1.5). The net movement of 
ions created within the organism essentially primes the system to allow for the site and direction 
selective flow of iron as well as other ions (Figure 1.5 Left). However in some cases the barrier 
of the missing protein cannot be surmounted and a disease phenotype is observed (Figure 1.5 
Middle). We hypothesized that because all of the other pumps and channels remain active, a 
site-specific iron gradient would accumulate upstream of the missing protein. Therefore if we 
could find a small molecule to not only bind that excess iron, but also mobilize it to release the 
gradient in a site- and direction- specific manner we could restore physiology downstream of the 
missing protein and treat the disease phenotype (Figure 1.5 Right). This approach is attractive 
because one could imagine it working in many different cases where iron is unable to move into, 
within or out of cells (Figure 1.6), representing a new generalizable approach to treating 









Figure	1.5	Build	up	of	 iron	 in	protein	 transporter	deficient	 systems.	A)	 	Iron	flows		






I consequently chose three different iron transporting proteins to study that represent a deficit in 
the movement of iron into cells, divalent metal transporter 1, DMT-1 (Figure 1.6 A); within cells 
mitoferrin MFRN1 and DMT1 (Figure 1.6 B) ; and out of cells ferroportin FPN1 (Figure 1.6 
C). I chose these proteins with the goal of learning whether a small molecule with protein-like 
function would be able to restore physiology via the site- and direction-selective movement of 
iron in systems missing integral iron transporting proteins, and how the iron regulatory system 
would respond to an exogenous iron delivery mechanism.  
 
1.6 DISCOVERY OF A SMALL MOLECULE IRON TRANSPORTER  
 In order to find a molecule that could not only bind iron but also transport it across 
cellular membranes my colleagues Anthony Grillo and Alexander Cioffi performed a directed 
screen of iron binding molecules. In order to efficiently screen a number of different candidates 
they used a modified functional complemen-tation experiment9, in which candidate compounds 
known or predicted to bind iron were tested for their capacity to restore growth to a strain of 







Figure 1.6 Iron is unable to move into (A) within (B) and out of (C) cells missing iron 
transporters creating site-specific iron gradients.     
A B C 
	 13 
1.7)56.  The assay is run by streaking a lawn of yeast on agar plates that do not allow the 
fet3Δftr1Δ yeast to grow, a disc impregnated with vehicle or compound is then placed on the 
plate where it diffuses outward in a circular fashion. We hypothesized that if the compound was 
able to bind iron, as well as tranpost it across the membrane and then allow the yeast cell to 
utilize the iron we would be able to see the yeast grow in a very distinctive “bullseye” pattern. 
The pattern is created by a zone of inhibition (due to high, toxic concentrations), followed by the 
zone of functional complementation, (due to intermediate, efficacious concentrations) followed 
by no growth due to insufficient concentrations for functional complementation.  
 The small molecule natural product hinokitiol (Hino, b-thujaplicin; Figure 1.8 A) was 
highly effective at restoring growth to the fet3Δftr1Δ yeast (Figure 1.8 B). Hinokitiol is a known 
metal chelator, that has been studied for its antifungal57, antimicrobial58 and anticancer59,60 
activity. Hinokitiol was originally isolated by Japanese chemist Tetsuo Nozoe in 1935 from the 
Figure 1.7 Schematic of the fet3Δftr1Δ yeast used in the modified functional 
complementation assay. The mutated fet3Δftr1Δ yeast are unable to grow under normal 
laboratory conditions (left). Small molecule mediated rescue of growth in fet3Δftr1Δ yeast 
(right).  
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essential oils of the Chamaecyparis taiwanensis, or Taiwan Hinoki tree61. While hinokitiol is 
found at very low concentrations in the Hinoki tree it is abundant in the bark of many species of 
trees including Thuja plicata Donn,  (The Western Red Cedar) and Cupressus lusitanica 
(Mexican Cypress)62 with reports of up to 0.04% of the bark’s biomass being comprised of 
hinokitiol.  
 
 With this exciting preliminary result in hand, I set out to characterize the rescue 
phenomena Anthony Grillo and Alexander Cioffi observed in the fet3Δftr1Δ yeast, expand the 
scope to mammalian cell lines and animals and explore the mechanisms that allowed for this 
imperfect small molecule to restore physiology.  The Screen mentioned above as well as portions 
of chapters to follow have been adapted from: Grillo, A. S.; SantaMaria A. M.; Kafina M. D.; 
Cioffi A.G.; Huston N. C.; Han M.; Seo Y. A.; Yien YY3, Nardone C.; Menon A. V.; Fan J.; 
Svoboda D. C.; Anderson J. B.; Hong J.D.; Nicolau B. G.; Subedi K.; Gewirth A. A.; Wessling-
Resnick M.; Kim J.; Paw B. H.; Burke M. D. “Restored iron transport by a small molecule 
Figure 1.8 Hinokitiol restores growth in fet3Δftr1Δ yeast. A) Structure of the small 
molecule hinokitiol (Hino). B) Growth of fet3Δftr1Δ yeast cells was restored by disc 






promotes absorption and hemoglobinization in animals” Science. 2017, 356, 608-616. Reprinted 
with permission from AAAS." 
 
1.7 METHODS  
 
Materials 
 Wild type (DEY1457) and isogenic fet3Δftr1Δ S. cerevisiae were obtained from D. 
Kosman56 Yeast were maintained on standard YPD media containing 10 g/L yeast extract, 20 
g/L peptone, and 20 g/L dextrose without (liquid media) or with (solid media) 20 g/L agar. 
Unless otherwise indicated, growth-restoration assays in yeast used a low iron SD media 
consisting of 1.91 g/L iron-free YNB-FeCl3 (ForMedium CYN 1201), 0.79 g/L Complete 
Supplement Mixture (Sunrise Science Products 1001-010), 5 g/L ammonium sulfate (Sigma 
A4418), 20 g/L dextrose, 10 µM FeCl3 (Sigma 451649, maintained in a glove box), and 10 µM 
hinokitiol (β-Thujaplicin, Sigma 469521) in 50 mM MES/Tris buffer at pH=7.0 without (liquid 
media) or with (solid media) 20 g/L agar. Dextrose and FeCl3 were added after autoclave 
sterilization from a filter-sterilized 40% w/v dextrose solution in water and from a freshly 
prepared 10 mM FeCl3 stock in sterile water, respectively.  
 
Phenotypic screen of growth rescue in fet3Δftr1Δ yeast with small molecules  
 Growth rescue in yeast was performed, similar to previously reported9, on low iron SD-
agar plates containing 50 mM MES/Tris buffer at pH=7.0, 2% agar, and 10 µM FeCl3. Yeast 
were grown overnight in YPD media and diluted to an OD600 = 0.1 in low iron SD media and 
streaked onto the low iron SD-agar plates. Stock solutions of candidate compounds (≥10 mM in 
DMSO) were impregnated onto filter paper discs and placed onto the streaked agar plates.  
Images were taken 48-72 hours after inoculation and incubation at 30 °C. 
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HINOKITIOL RESTORES PHYSIOLOGY IN CELLS AND ANIMALS 
 
2.1 INTRODUCTION 
 In this chapter, I will explore hinokitiol’s basic biophysical properties, from lipophilicy 
and metal selectivity, to iron binding and transport. I also probe hinokitiol’s ability to restore 
physiology in multiple protein iron transporter deficient mammalian cells lines and animals. 
These studies provide phenomenological evidence for the first time, that an imperfect, small 
molecule can replace a missing protein in an animal and thereby restore normal physiology.    
 Portions of the work presented in this chapter were preformed with aid from my 
colleagues Dr. Anthony Grillo, Dr. Alexander Cioffi, and Dr. Bruno Nicolau our undergrads 
Dillon Svoboda, Chris Nardone, James Fan, John Hong, Jake Anderson, and Tejashri Venkatesh 
and my high school student Angela Li. Animal studies were performed with our collaborators 
Archita Menon and Murui Han from Jonghan Kim’s Lab at Northeastern University (Belgrade 
Rat), Young Ah Seo and Marianne Wessling-Resnick at Harvard Medical School (Flatiron 
Mice), as well as Dr. Yvette Yien, Nick Huston, and Martin Kafina from Barry Paw’s Lab at 
Harvard Medical School (Zebrafish). Portions of this chapter have been adapted from Grillo, A. 
S.; SantaMaria A. M.; Kafina M. D.; Cioffi A.G.; Huston N. C.; Han M.; Seo Y. A.; Yien Y.Y.; 
Nardone C.; Menon A. V.; Fan J.; Svoboda D. C.; Anderson J. B.; Hong J.D.; Nicolau B. G.; 
Subedi K.; Gewirth A. A.; Wessling-Resnick M.; Kim J.; Paw B. H.; Burke M. D. “Restored iron 
transport by a small molecule promotes absorption and hemoglobinization in animals” Science. 





2.2 CHARACTERIZATION OF HINOKITIOL IRON BINDING AND TRANSPORT 
 In order to probe the mechanism which allows for hinokitiol to rescue the growth 
phenotype in iron deficient yeast we first wanted to understand its basic biophysical properties. 
Specifically, we hypothesized that hinokitiol mediated growth is due to its ability to transport 
iron through cell membranes into the cytoplasm where the iron is released and therefore 
available for necessary cellular processes. However, with only the results of the disc diffusion 
assay in hand it was possible that hinokitiol was allowing for growth due to another, unexpected, 
off-target effect.  
 We found that hinokitiol binds iron as evident by a shift in its UV spectrum upon titration 
with iron (Figure 2.1 A) and that hinokitiol is able to bind iron that is weakly associated with 
common iron chelating small molecules found abundantly in cells (Figure 2.1 B). The alpha-
hydroxy ketone in hinokitiol is thought to be an essential part of its iron binding motif, therefore 
we synthetically removed a single oxygen atom at the C2 position by hydrogenolysis (Figure 2.1 
C). This two-step synthesis yielded C2-deoxy hinokitiol or C2deOHino a derivative that is 
unable to bind iron, as evident by the lack of shift seen in its UV spectra upon titration with iron 
(Figure 2.1 D). Hinokitiol is able to mobilize ferrous (Figure 2.1 E) and ferric (Figure 2.1 F) 
iron from model liposomes while C2deOHino, Deferirone1, a clinically approved iron chelator 
and pyridoxal isonicotinoyl hydrazone (PIH)2, an iron chelator from the literature shown to 
mobilize cellular iron, were all unable to do so (Figure 2.1 E and F). These data coupled with 
the results of the yeast screen lead us to choose hinokitiol as the primary candidate for further 






Figure 2.1 Hinokitiol binds and transports iron. (A) UV-vis titration study of hinokitiol 
with increasing FeCl3 indicates that hinokitiol binds iron. Arrows indicate changes in the UV 
spectrum with increasing iron from 0:1 Fe:Hino (light blue line with least absorbance at 420 
nm) to 6:1 Fe:Hino (black line). (B) Hinokitiol binds iron (III) using a source of ionic iron 
(III) and iron (III) weakly bound to small molecules. (C) The transport inactive derivative, 
C2-deoxy hinokitiol (C2deOHino), was synthesized on multi-gram scale in two steps from 
hinokitiol. (D) C2deOHino does not bind iron. (E and F) In contrast to deferiprone, PIH and 
C2deOHino, hinokitiol autonomously promotes the efflux of (E) ferrous and (D) ferric iron 
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2.3 CHARACTERIZATION OF HINOKITIOL IRON TRANSPORT IN YEAST 
 Based on the efflux data as well as the initial screen mentioned in chapter one, a striking 
trend arose when the compounds that restore transport iron across lipid membranes as well as 
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Figure 2.2 Small molecule-mediated growth is general to lipophilic carriers. A) Hinokitiol 
and other lipophilic α-hydroxy ketones restore growth to fet3Δftr1Δ yeast streaked onto low 
iron SDagar plates containing 10 µM FeCl3 while B) other, more hydrophilic iron chelators 
and C) small molecule transporters of other ions do not restore growth under identical 
conditions. D) X-ray crystal structure of a C1-symmetric Fe(Hino)3 complex. E) In contrast 
to water soluble chelators, such as deferiprone, the hinokitiol-iron complex partitions into 
nonpolar solvents. F) Octanol/water partition coefficients of the iron complexes of other iron 
chelators that do or do not restore growth to fet3Δftr1Δ yeast.  
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(PIH)2, and salicylaldehyde isonicotinoyl hydrozone 
(SIH)3,4 were unable to promote growth of the 
fet3Δftr1Δ yeast (Figure 2.2 B) while hinokitiol, 
tropolone and maltol were able to vigorously 
promote growth (Figure 2.2 A).  We discovered 
that in general, chelators which form lipophilic iron 
complexes were efficacious (Figure 2.2 A, E, F), 
while more hydrophilic iron chelator complexes 
(Figure 2.2 B, E, F) or other non-iron binding 
transporters (Figure 2.2 C) were not. We 
hypothesized that in the case of hinokitiol, the 
isopropyl groups form a lipophilic cage around a 
hydrophilic ferric-iron binding core, allowing for 
the Fe:Hino complex to pass through lipid 
membrane and Anthony Grillo was able to obtain a 
high resolution crystal structure of Fe(Hino)3 which 
supports this hypothesis (Figure 2.2 D). The Fe:Hino complex is so lipophilic compared to 
deferiprone that you can readily see the difference by eye (Figure 2.2 E) and quantitatively 
(Figure 2.2 F) in partitioning experiments. Interestingly when my high school student, Angela 
Li, and I synthesized more lipophilic derivatives of deferiprone, they were able to restore yeast 
growth (Figure 2.3). This further supports the hypothesis that lipophilicity is a key contributing 
factor that determines whether an iron binding small molecule is able to restore growth in iron 









































































































































































































































































































































































































































Figur  2.3 Lipophilic derivatives of
deferiprone are able to recue iron 
deficient yeast growth. Disc diffusion 
assays performed under identical 
conditions to those in figure 2.2 with 
lipophilic derivatives of deferiprone.   
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 Continuing to explore the rescue phenomena in yeast we found that hinokitiol allows the 
yeast to grow as vigorously as wild type (Figure 2.4 A), was independent of the yeast 
siderophore proteins Arn1-45 (Figure 2.4 B) , and was sustainable on non-fermentable glycerol 
media (Figure 2.4 C). Of special importance is the ability of hinokitiol to restore growth in yeast 
without their siderophore proteins present. There are currently no known equivalent siderophore 
scavenging proteins in humans and therefore a siderophore protein mediated rescue of yeast 
growth would not have been translatable to human health and therefore of less interest for future 
study.  
 To further demonstrate that the growth we were observing in the fet3Δftr1Δ yeast treated 
with hinokitiol was in fact iron dependent, my colleagues Anthony Grillo and Alexander Cioffi 
were able to show that hinokitiol causes an influx of 55Fe in the fet3Δftr1Δ yeast that is similar to 
that of the wild type  (Figure 2.5 A). We then demonstrated that the hinokitiol mediated 
restoration of growth is vigorous and gets up to wild type levels (Figure 2.5 B) occurs over a 
Figure 2.4 Hinokitiol restores growth to fet3Δftr1Δ yeast robustly, independently of 
siderophore proteins and on both fermentable and non-fermentable media.  A) In the 
absence of hinokitiol, reduced fet3Δftr1Δ yeast cell growth was observed on low-iron SD agar 
plates containing 10 µM FeCl3 by serial 10-fold dilution plating  [from OD600 (optical 
density at 600 nm) = 1.0]. Under identical conditions, but in the presence of 10 µM hinokitiol, 
restored cell growth was observed on the same low-iron SD agar plates. B) Hinokitiol (10 
µM) also restores growth to iron-deficient yeast missing all known siderophore protein 
transporters (fet3Δarn1-4Δ) on low iron SD-agar plates containing 10 µM FeCl3. C) 10-fold 
serial dilution plating (from OD600 = 1.0) of iron-deficient yeast (fet3Δftr1Δ) on low iron 






























range of concentrations up to ~62 µM hinokitiol  (Figure 2.5 C), has a similar doubling time to 
wild type yeast (Figure 2.5 D, E) and is iron concentration dependent (Figure 2.5 F). 
C2deOHino, which is unable to bind or transport iron (Figure 2.1 C-F), is also unable to restore 
iron influx (Figure 2.5 A) or restore yeast growth at any concentration tested (Figure 2.5 C), 
further demonstrating that hinokitiol rescue is due to iron mobilization.  
 In order to probe the sustainability of hinokitiol mediated rescue I treated fet3Δftr1Δ 
hinokitiol and switched the cultures back and forth between solid and liquid low iron SD media 
repeatedly and checked growth quantitatively in the liquid growth stage by OD600 after 48 hours 
of incubation. I found that Hinokitiol mediated growth is sustainable for over 110 days (Figure 
2.5 G), and if at any point during the experiment hinokitiol was removed from the assay the 
fet3Δftr1Δ yeast were unable to grow. This loss of growth upon denying hinokitiol to the 
fet3Δftr1Δ yeast is important because it indicates that the long-term sustained growth was not 
due to genetic drift and loss of phenotype, but actually a function of hinokitiol rescue.  
 With the validation of our negative probe, C2DeOHino, and all of the biophysical, 
phenomenological and mechanistic data in hand we were even more confident that hinokitiol’s 
unique properties made it a promising lead compound toward developing a small molecule iron 
transporter to treat diseases of iron homeostasis. We therefore chose three mammalian proteins 






 Figure 2.5 Hinokitiol causes the influx of iron into yeast cells and causes robust 
restoration of growth. A) Hinokitiol increased 
55
Fe influx into fet3Δftr1Δ yeast, whereas 
C2deOHino did not (n = 3). B) Yeast cell growth in liquid SDmedia containing 10 µM FeCl3 
in the absence or presence of 10 µM hinokitiol (n = 3). NS, not significant; ****P ≤ 0.0001. 
C) Hinokitiol restored growth of fet3Δftr1Δ yeast, whereas C2deOHino did not (n = 3). D 
and E) Hinokitiol treated fet3Δftr1Δ yeast have similar growth kinetics and doubling time 
compared to wild type. F) Hinokitiol-promoted growth restoration of fet3Δftr1Δ yeast is 
dependent on iron levels in the media (n=3). G) Growth restoration to fet3Δftr1Δ yeast can be 
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2.4 HINOKITIOL RESTORES IRON MOBILIZATION INTO CELLS  
 Divalent Metal Transporter 1 (DMT1) is the sole non-heme iron transporter present in the 
apical, microvillus membrane of gut enterocytes (Figure 2.6 left) 6,7 and is therefore the main 
gateway through which iron from the diet is absorbed. In humans, DMT1 mutations cause an 
extremely rare form of microcytic anemia that does not respond to iron supplementation orally or 
intravenously due to the peripheral function of DMT1 in red blood cell progenitors7–14(Figure 
2.6 right).  These patients present with severe anemia, high reticulocyte count and occasionally 
iron overload15.  
  
 DMT1 mutations only contribute to 5-10 cases of microcytic anemia world wide, it is 
considered an extremely a rare disease and therefore there remain few treatment options for 
patients. Chelation therapy has been attempted in order to reduce the liver iron burden in patients 
Enterocyte
Reticulocyte
Figure 2.6 DMT1 is found in both gut enterocytes (left) and red blood cell progenitors 




with hepatic iron overload, however it is often ineffective and occasionally actively harmful to 
the patient’s health. Chelators were found to be ineffective at removing iron from the liver or led 
to a drop in hemoglobin level that was deemed unsafe and the treatment regimen was thus was 
interrupted (G. Tchernia  C. Beaumont, unpublished data, 2007)16. With these challenges in mind 
we asked whether hinokitiol could promote iron mobilization into cells and therefore restore 
down stream physiology in a DMT1 deficient system.  
 We first studied iron uptake and transepithelial transport in fully differentiated DMT1-
deficient Caco-2 gut epithelia monolayers (Figure 2.7 A). In order to make a stable knockdown 
of DMT1 in the Caco-2 cells we utilized stable short hairpin RNA (shRNA) transfection17,18 and 
selected the clones with the greatest, and most consistent knock down of iron 55Fe transport 
(Figure 2.7 D). We then characterized DMT1 expression via mRNA expression (Figure 2.7 B) 
and protein quantification (Figure 2.7 C) via quantitative PCR (qPCR) and western blot 
respectively. Control Clone A was found to have the highest 55Fe transport and shDMT1 Clone 
4A was found to have the most diminished 55Fe transport and so both were chosen for further 
study in order to give the greatest delta that hinokitiol would have to overcome. Importantly in 
the presence of hinokitiol we do not observe an increase in DMT1 protein production, therefore 
any effects we see in the shDMT1 membranes are not due to an off target increase in DMT1 






Figure 2.7 Characterization of shDMT1 Caco-2 cells. (A) DMT1-deficient gut epithelia 
exhibit reduced dietary iron absorption across the apical membrane resulting in decreased 
transport to the basolateral fluid. (B) Dmt1 mRNA levels, quantified via qRT-PCR, are 
reduced in shDMT1 Caco-2 monolayers as compared to the shControl cell monolayers. N = 
9. (C and D) Quantitative densitometric analysis of western blots indicated decreased DMT1 
protein levels in shDMT1 Caco-2 monolayers. Hinokitiol (500 nM) treatment did not induce 
DMT1 expression. N = 13-14. E) Iron-55 transport assay performed on shDMT1 clone 
membranes 14-21 days after seeding. Control Clone A and shDMT1 Clone 4A were the best 
control and knock down lines respectively at the 1 hour time point and were chosen for 
further study (N=3) .  



































































































































































 Relative to wild-type controls, DMT1-deficient monolayers (Figure 2.8 A) showed 
reduced iron uptake into cells and reduced transepithelial iron transport to the basolateral fluid 
after apical addition of a trace amount (200 nM) of 55FeCl3 (Figure 2.8 B and C). Apical 
addition of just 500 nM of hinokitiol restored uptake and transport to control levels (Figure 2.8 
B and C) over 4 hours, a time frame commensurate with dwell times in the gut (Figure 2.8 D). 








































































































































pH 5.5 6.5 7.4
D E F 
Figure 2.8 Hinokitiol Restores Iron uptake and therefore transport in DMT1 Deficient 
Caco-2 monolayers. (A) Bright field microscope image 40x ofshDMT1 Caco-2 monolayers. 
(B) 
55
Fe uptake into DMT1-deficient (shDMT1) Caco-2 monolayers and (C) transepithelial 
transport (apical to basolateral) indicated that hinokitiol (500 nM) restored normal iron 
absorption (n = 3). shControl refers to Caco-2 monolayers that were transfected with a non-
targeting control shRNA plasmid. (D) Hinokitiolpromoted 
55
Fe transport occurs on time 
scales commensurate with dwell times in the gut (n = 3). (E) Transepithelial electrical 
resistance (TEER) values of Caco-2 monolayers treated with DMSO, hinokitiol (500 nM), or 
C2deOHino (500 nM) remain consistent over the course of the experiment. N = 3. (F) 
Hinokitiol (500 nM) promotes transport in shDMT1 Caco-2 monolayers at a range of pHs 
found throughout the duodenum. N = 3. 
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experiment tracked extremely well with the control membranes indicating that the system is 
working well with the exogenous transport of iron.  
  Importantly, hinokitiol did not disrupt monolayer integrity (Figure 2.8 E), indicating 
that the monolayers remained intact and any iron transport observed was trasnepithelial and not 
due to loss of tight junctions and therefore a simple “leak” of iron transcellularly between the 
cells within the membrane. Hinokitiol caused no observable toxicity as evident by a WST-8 
assay (EC90 >100 µM), and did not affect basal DMT1 expression as evident by western blot 
quantification after 4 hours of hinokitiol treatment (Figure 2.7 C and D). Hinokitiol-mediated 
transport occurred across a wide range of pHs found in the gut throughout the duodenum and 
increased with decreasing pH (Figure 2.8 F). This further supports that this is a hinokitiol 
mediated phenomena because proteins have the opposite trend where more uptake and transport 
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Figure 2.9 Hydrophilic iron chelators do not restore iron transport in Caco-2 
monolayers. In contrast to hinokitiol, the iron chelators deferiprone, PIH, SIH, and 
deferoxamine do not simultaneously restore (A) uptake into or (B) transcellular transport 
across DMT1-deficient Caco-2 monolayers under identical conditions (pH = 5.5 apical, pH = 
7.4 basolateral). Dotted line represents shControl levels. While a slight increase in transport 
was observed in SIH treated cells, reduced uptake was observed, consistent with paracellular, 
and not transcellular, iron transport. Concentrations used for each small molecule were 0, 




 Whereas hinokitiol promoted uptake and transport over a wide range of concentrations, 
C2deOHino (Figure 2.8 A, B), and subtoxic concentrations of the iron chelators deferiprone, 
deferoxamine, PIH, and SIH did not promote either uptake or transport (Figure 2.9 A and B). 
High concentrations of these more hydrophilic iron chelators instead decreased iron uptake into 
DMT1-deficient monolayers (Figure 2.9 A) corroborating the negative results seen in DMT1 
patients treated with the same chelators. These data demonstrate that hinokitiol is able to 
mobilize iron into cells and therefore restore iron uptake and transepithelial transport in a 
mammalian tissue culture system.  
 
2.5 HINOKITIOL RESTORES MOBILIZATION OF IRON WITHIN CELLS  
 As stated in the previous section DMT1 is also very important peripherally to iron 
absorption in the gut, it is also necessary for hemoglobinization and differentiation of red blood 
cell progenitors (Figure 2.6 B)9,19,20. If DMT1 is missing, depleted, or hypomorphic, intracellular 
iron(II) efflux from endosomes of erythroid precursors is precluded, thus preventing 
hemoglobinization and differentiation in mature red blood cells (Figure 2.10 A)21–23. In order to 
study hinokitiol’s ability to transport iron within DMT1 deficient cells, we made stable 
knockdown cell lines with shDMT1 in DS19 murine erythroleukemia (MEL) cells24. We 
quantified DMT1 expression via mRNA expression (Figure 2.10 C) and protein quantification 
(Figure 2.10 B and D) with quantitative PCR (qPCR) and western blot respectively. We then 
chose the shDMT1 clones with the best DMT1 knock down, shDMT1 Clone 1, 2 and 4, for 





 We tested for dimethyl sulfoxide (DMSO)–induced differentiation and 
hemoglobinization in DS19 murine erythroleukemia (MEL) cells24 and shRNA transfected 
DMT1-deficient MEL cells in the absence or presence of hinokitiol. shControl cells 
differentiated normally after 3 days as indicated by the characteristic pink color of hemoglobin in 
cell pellets (Figure 2.11 A). We were able to quantify the differentiation of each clone by 
staining with o-dianisidine (Figure 2.11 C and D). Dianisidine specifically stains 
hemoglobinized cells; when heme is present in a cell the iron in the heme along with H2O2 react 
and oxidize the dianisidine to form a dark brown color which in turn stains the cell. These cells 


















































































































Figure 2.10 Characterization of shDMT1 MEL cells. (A) DMT1 deficiencies impair 
normal differentiation of red blood cell progenitors by precluding endosomal iron release to 
the cytosol for mitochondrial hemoglobinization. (B) Representative western blot image of 
DMT1 protein levels in differentiated MEL cells. (C) Dmt1 mRNA (N = 12-16) and (D) 
DMT1 protein levels are reduced in shDMT1 MEL cells (Clones 1, 2, and 4) relative to 
shControl after DMSO induction for terminal differentiation. N = 13.  
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was observed in DMT1-deficient cells (Figure 2.11 A-D). Three days of hinokitiol treatment (1 
mM) restored 55Fe incorporation into heme (Figure 2.11 D), and hemoglobinization (Figure 
2.11 A-D). The efficacious concentration of hinokitiol was over an order of magnitude higher 
than the dose found to be toxic (determined via WST-8, EC90 =24). C2deOHino had no effect 
(Figure 2.11 C and D) and, as expected, no differentiation or staining was observed in the 
absence of DMSO, with or without hinokitiol treatment. Collectively, these studies demonstrate 
that hinokitiol is able to move iron within cells and therefore allow for restoration of physiology, 
in this case restoration of hemoglobinization and differentiation.  
 
Figure 2.11 Hinokitiol Restores hemoglobinization in DMT1 Deficient MEL cells. (A) 
Cell pellets from shControl and hinokitiol-treated (1 µM) DMT1-deficient MEL cells appear 
pink, characteristic of hemoglobin, whereas DMT1-deficient cell pellets do not.  (B) 
Hinokitiol (1 µM for three days) visually restores differentiation as evidenced by staining 
hemoglobinized cells brown with o-dianisidine. (C) ImageJ quantification of MEL cells 
stained brown with o-dianisidine (n= 6 -48). The dashed line represents shControl levels. (D) 
55
Fe incorporation into heme in hinokitiol rescued DMT1-deficient MEL cells (n= 3-23). The 
dashed line represents shControl levels. 





















































































2.6 HINOKITIOL RESTORES MOBILIZATION OF IRON OUT OF CELLS  
 With evidence that hinokitiol is able to mobilize iron into and within cells we next probed 
its ability to mobilize iron out of cells. Ferroportin is an important iron exporter that is highly 
expressed in both the duodenum and liver macrophages and therefore involved in both iron 
absorption and iron recycling within the body (Figure 1.6) 20,25,26.  Hemochromatosis Type IV, 
or The ferroportin Disease, is caused by dominant negative mutations in FPN1 leading to iron 
overload and interestingly a concomitant anemia characterized by hypoferremia	 and	 liver	
macrophage	iron	loading27. The iron overload in the liver can lead to cirrhosis and therefore, as 
mentioned in chapter 1, the recommended treatment is phlebotomy27,28. The problem with this 
treatment is that some patients have a very low tolerance to phlebotomy due to the inherent low 
iron absorption and therefore the anemia that is characteristic of the disease. There are over 200 
confirmed patients world wide with that number growing as the disease becomes more 
recognized.  
 In order to study the effect of FPN1 deficiency on iron efflux across the basolateral side 
of fully differentiated Caco-2 monoloayers (Figure 2.12 A), we utilized the small molecule 
inhibitor quercetin (Figure 2.12 B). Quercetin is a natural product found in many of the foods we 
consume including apples, onions, and tea29. It is the most abundant dietary flavonoid and makes 
up about 25% of the total flavonoid intake in an average diet which corresponds to 10-20 
mgs/day29. In a study by Lusjek et al it was found that quercetin specifically upregulates a single 
miRNA (miR-17-3p) which interacts with interaction with the FPN1 3’UTR29. This interaction 
causes a decrease in FPN1 protein expression and leads to a FPN1 deficient state29.  After 
treating fully differentiated Caco-2 monolayer with quercetin for 18 hours, the quercetin was 
removed and the FPN1 protein levels were checked via western blot to confirm satisfactory 
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knock down as compared to wild type (Figure 2.12 C and D).  
 
 FPN1 deficiencies reduce iron efflux across the basolateral membrane of gut epithelia 
(Figure 2.13 A). Hinokitiol (1 µM) restored transepithelial iron transport in FPN1-deficient 

















































Figure 2.12 FPN1 knock down in Caco-2 monolayers by quercetin. (A) Quercetin, a 
flavonoid natural product that causes miRNA mediated knockdown of ferroportin. (B) 
FPN1 deficiencies prevent the proper release of iron from gut enterocytes leading to 
reduced transport to the basolateral fluid.  (C and D) Quercetin incubation for eighteen 
hours knocks down FPN1 protein levels in Caco-2 cells; hinokitiol (1 µM) does not 
increase FPN1 levels. N = 8. 
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(Figure 2.13 B). Importantly iron uptake, which is ferroportin independent was not affected with 
hinokitiol treatment (Figure 2.13 C). Hinokitiol treatment after treatment after pretreatment with 
quercetin did not disrupt monolayer integrity (Figure 2.13 D). 
 
 FPN1 is also important in iron recycling in liver macrophages called Kupffer cells 
(Figure 1.6 right). In order to recycle iron the Kupffer cells phagocytose senescent erythrocytes, 
digest them and then efflux the iron into the blood where it is bound by transferrin and circulated 
A B 
C D 
Figure 2.13 Hinokitiol restores iron transport in FPN1 deficient Caco-2 monolayers. (A) 
1 µM Hinoktiol restores 
55
Fe transepithelial transport across FPN1-deficient Caco-2 
monolayers (B) over 4 hours (C) without affecting iron uptake (n = 12) or (D) disrupting 
































































































































through out the body (Figure 1.3)30,31. In order to make FPN1 deficient macrophages we treated 
them with the peptide hepcidin. Hepcidin is a small regulatory peptide, or hormone, that 
regulates iron absorption and recycling within the body31–34. When there is high iron in the blood 
hepcidin is upregulated and then binds to, and downregulates ferroportin in both the gut and liver 
(Figure 2.14 A). This stops the absorption of iron from the diet as well as iron recycling in the 
liver31 in order to keep free, non-transferrin bound iron out of the blood. We therefore used 
hepcidin to make FPN1 deficient J774 mouse reticuloendothelial macrophages (Figure 2.14 B)35 
and quantified the FPN1 protein knockdown via western blot (Figure 2.14 C and D) . 
 Hepcidin decreased the amount of iron efflux out of J774 macrophages (Figure 2.15 A). 




















































Figure 2.14 Characterization of hepcidin knock down of FPN1 in J774 Macrophages. (A) 
Hepcidin downregualtes FPN1 in both the liver and the gut. (B) FPN1 deficiencies preclude 
the release of labile iron from reticuloendothelial macrophages in the liver (C and D) 
Hepcidin reduces FPN1 levels in J774 macrophages; hinokitiol (5 µM) does not increase 
FPN1 levels. N = 20. 
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restoration of efflux with hinokitiol was time dependent (Figure 2.15 B) as well as dose-
dependent (Figure 2.15 C). The restored iron release from FPN1-deficient J774 macrophages 
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Figure 2.15 Hinokitiol restores iron efflux from FPN1 deficient Caco-2 monolayers and 
J774 Macrophages. (A) Hinokitiol (5 μM) promotes the release of 55Fe from hepcidin-
treated FPN1- deficient J774 macrophages (t = 2 hours; n = 6 to 20). (B) Time-dependent 
release of 55Fe from wild-type J774 macrophages and FPN1-deficient J774 macrophages 








2.7 HINOKITIOL RESTORES IRON MOBILIZATION AND THEREFORE 
PHYSIOLOGY IN MULTIPLE ANIMAL MODELS MISSING IRON TRANSPORTERS 
  With all of the promising data we collected in cellular systems we were thus encouraged 
to ask whether hinokitiol could restore gut iron absorption and hemoglobinization in animal 
models of these iron-transporter deficiencies. DMT1 deficiencies in duodenal enterocytes reduce 
rates of iron absorption in the gut by disrupting apical iron uptake into cells21,22,30,36. We 
therefore tested gut iron absorption in DMT1-deficient Belgrade (b/b) rats, the leading animal 
model of DMT1 deficiencey37. Homozygous Belgrade rats are much smaller than their 
littermates (Figure 2.16 A) with a low survival rate and life expectancy,37 along with low 
hemoglobin and hematocrit. They have a high reticulocyte count thought to be caused by 
immature reticulocytes being released by the marrow to compensate for the anemic phenotype37.  
 We tested hinokitiol’s ability to restore gut iron absorption upon administration of a 
single dose of 59Fe and 1.5 mg of hinokitiol per kilogram of body weight via oral gavage. Higher 
doses of hinokitiol are reported to be nontoxic in rats subjected to chronic oral administration for 
2 years38. Similar to the reduced iron absorption previously reported in b/b rats37, a twofold 
reduction in 59Fe absorption was observed in C2deOHino treated b/b rats relative to sibling 
controls (+/+ or +/b) (Figure 2.16 B). Treatment of b/b rats with hinokitiol increased 59Fe 
absorption back to control levels after 1 hour (Figure 2.16 B and C). There is a slight dip of 59Fe 
concentration in the blood at 120 min in the hinokitiol treated rats (Figure 2.16 C), however that 
correlates with a concomitant increase in 59Fe in the kidney and the femur (Figure 2.16 D and 
E). This is encouraging because after just one dose of hinokitiol we are starting to see the iron 
move into the tissues, indicating that not only is there an increase in iron absorption but that iron 





 We next looked at the Flatiron mouse, the leading model of genetic FPN1 deficiencey 
and The Ferroportin Disease or Hemochromotosis Type IV.  Flatiron mice have a dominant 
negative mutation in their FPN1 gene and therefore have reduced hematocrit and liver iron 
overload, similar to the phenotype seen in the clinic39. Similarly to the Belgrade rat we tested 
hinokitiol’s ability to restore gut iron absorption upon administration of a single dose of 59Fe and 
1.5 mg of hinokitiol per kilogram of body weight via oral gavage. Consistent with our 






























































































































Figure 2.16 Hinokitiol restores iron absorption in the Belgrade rat (A) A difference 
between day old Belgrade rat littermates is already noticeable between the homozygous (b/b, 
left) and heterozygous (b/+, right). (B) Oral gavage of 1.5 mg/kg hinokitiol promotes the gut 
absorption of 
59
Fe into DMT1-deficient Belgrade (b/b) rats. (C) Time-dependent gut iron 
absorption in Belgrade (b/b) and healthy (+/+ or +/b) rats treated with vehicle, hinokitiol or 
C2deOHino. (D and E) 
59
Fe in (D) femur and (E) kidney after 4 hours in rats after oral gavage 
with vehicle, hinokitiol (1.5 mg/kg), or C2deOHino (1.5 mg/kg).  
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Hinokitiol increased 59Fe absorption in ffe/+ mice after 1 and 2 hours (Figure 2.17 A). Hinokitiol 
reduced the liver non-heme iron burden in the Flatiron with chronic treatment (Figure 2.17 B). 
With increased iron absorption from the diet (Figure 2.17 A), coupled with the increased iron 
recycling in the liver (Figure 2.17 B) after chronic treatment we observed a concomitant 






















































































































Figure 2.17 Hinoktiol restores iron absorption in FPN1 deficient flatiron mice. (A) Oral 
gavage of 1.5 mg/kg hinokitiol promotes the gut absorption of 
59
Fe into FPN1-deficient 
flatiron (ffe/+) mice after 1 (left) and 2 hours (right) (n = 4-7). (B and C) Chronic IP injection 
of Hino (3 mg/kg) daily for 1 week causes a (B) release of iron from the liver and an (C) 





 In the Belgrade rat we were able to show increased gut iron absorption however, due to 
the sickly nature of the rats we were unable to perform chronic studies. Instead of doing chronic 
studies in the rat we next moved onto zebrafish. Danio rerio is well established as a powerful 
model organism in the study of hematopoiesis41.  We therefore used it to test whether chronic 
treatment with a small molecule iron transporter could restore hemoglobinization in both Dmt1 
and Mfrn1 deficiencies19,42. We first performed morpholino-mediated transient knockdown of 
Dmt1 in a Tg(globinLCR:eGFP) zebrafish strain expressing green fluorescent protein (GFP)–
tagged erythrocytes (Figure 2.18 A bottom)43. Injection of a designed antisense morpholino 
targeting the exon 4–intron 4 junction of premature dmt1 mRNA reduced steady-state dmt1 
levels (Figure 2.18 A top) and decreased the number of GFP positive erythroid cells detected by 
fluorescence activated cell sorting (FACS) analysis (Figure 2.18 B). Addition of hinokitiol to the 
embryo media 24 hours post fertilization (hpf) and incubation for an additional 2 days promoted 
hemoglobinization in these DMT1-deficientmorphant zebrafish without observable toxicity, 
whereas C2deOHino had no effect (Figure 2.18 B). Using the same morpholino approach we 
looked at Mfrn1 and hemoglobinization in Mfrn1-deficient morphant Tg(globinLCR:eGFP) 
zebrafish)42,43. Our collaborators have previously shown restoration of hemoglobinization in 
Mfrn1-deficient zebrafish through ectopic expression of Mfrn1 protein with complementary 
RNA42. Forty-eight hours of hinokitiol treatment restored hemoglobinization and the number of 
GFP-positive erythrocytes in these morphants (Figure 2.18 C). We further tested whether 
hinokitiol could similarly restore hemoglobinization in genetically mutated chardonnay 
(cdyte216) zebrafish, which contain a nonsense mutation leading to truncated Dmt1 and thereby 
exhibit severe hypochromic, microcytic anemia19. A heterozygous cross of +/cdy fish  (Figure 
2.18 D) led to a Mendelian distribution of ~75% healthy (+/+ and +/cdy) and ~25% anemic 
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(cdy/cdy) embryos in each clutch after o-dianisidine staining 72 hpf (Figure 2.18 E). Hinokitiol 
treatment for 2 days increased the number of fish exhibiting high hemoglobin levels, whereas 
C2deOHino had no effect (Figure 2.18 E). Last, following a similar approach, we tested whether 
hinokitiol could restore hemoglobinization in genetically mutated frascati (frstq223) zebrafish, 
which contain a missense mutation leading to an inactive Mfrn1 mitochondrial protein and 
profound anemia during embryogenesis42,44. Hinokitiol treatment of embryos collected from a 
heterozygous cross of +/frs fish prevented the anemic phenotype (Figure 2.18 F). Genotyped 
(Figure 2.18 G) healthy larvae (+/+ and +/frs) exhibited brown staining with o-dianisidine, 
whereas untreated frs/frs fish did not (Figure 2.18 G). Hinokitiol treatment restored brown 
staining to frs/frs fish (Figure 2.18 G). As expected, hinokitiol did not affect sauternes 
(sautb223) zebrafish45 deficient in the initial enzyme involved in porphyrin biosynthesis (Alas2) 
indicating the specificity of hinokitiol effects to defects in iron transport. 
 Collectively these studies represent the first time we have seen a small molecule mimic a 
protein in a whole animal and restore downstream physiology. We have shown that hinokitiol 
can move iron into, within and out of cells. The next, logical step was to discover how an 
imperfect small molecule was able to accomplish this. The next two chapters focus on the 
mechanistic underpinnings that allow hinokitiol to harness the gradients created by the missing 
iron transporters it is replacing, as well as how it interfaces with the endogenous regulatory 
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 Figure 2.18 Hinokitiol Restores Hemoglobinization in Zebrafish. (A) Top: Morpholino-
mediated knockdown of steady-state Dmt1 mRNA in Tg(globinLCR:eGFP) fish as 
determined by semi-quantitative RTPCR with β-actin as a loading control.   Bottom: Image of 
a zebrafish with GFP-tagged erythrocytes (J. J. Ganis et al., Dev. Biol  366. 185-194. 2012). 
(B and C) Hinokitiol treatment (1 µM) added to the embryo media (containing 10 µM iron 
citrate) at 24 hpf and incubation for an additional 48 hours increases the number of GFP-
positive erythroids (detected by FACS analysis) in (B) Dmt1-deficient and (C) Mfrn1-
deficient morphant zebrafish from a line of transgenic fish containing GFP tagged erythroids 
(n = 7 to 17). (D) Heterozygous cross of cdy/+ zebrafish yields 75% non-anemic fish 25% 
anemic fish due to mendelian genetics. (E and F) Hinokitiol decreases the number of anemic 
fish from a heterozygous cross of (E) +/cdy fish, and (F) +/frs fish as determined by o-
dianisidine staining, whereas C2deOHino does not. (G) Embryos from a heterozygous cross 
of +/frs fish were genotyped by restriction enzyme digestion with BsrI restriction enzyme. 
Lanes 4 and 5 correspond to frs/frs fish treated with hinokitiol for 48 hours. (H) Hinokitiol-
treated frs/frs fish stain brown with o-dianisidine, whereas anemic frs/frs fish do not, 
indicating increased hemoglobin levels after hinokitiol treatment. 
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2.8 METHODS            
Materials 
 Wild type (DEY1457) and isogenic fet3Δftr1Δ S. cerevisiae were obtained from D. 
Kosman46. Wild type (YPH499) and isogenic fet3Δarn1-4Δ S. cerevisiae were obtained from C. 
Philpott47. Yeast were maintained on standard YPD media containing 10 g/L yeast extract, 20 
g/L peptone, and 20 g/L dextrose without (liquid media) or with (solid media) 20 g/L agar. 
Unless otherwise indicated, growth-restoration assays in yeast used a low iron SD media 
consisting of 1.91 g/L iron-free YNB-FeCl3 (ForMedium CYN 1201), 0.79 g/L Complete 
Supplement Mixture (Sunrise Science Products 1001-010), 5 g/L ammonium sulfate (Sigma 
A4418), 20 g/L dextrose, 10 µM FeCl3 (Sigma 451649), and 10 µM hinokitiol (β-Thujaplicin, 
Sigma 469521) in 50 mM MES/Tris buffer at pH=7.0 without (liquid media) or with (solid 
media) 20 g/L agar. Dextrose, hinokitiol, and FeCl3 were added after autoclave sterilization from 
a filter-sterilized 40% w/v dextrose solution in water, from a freshly prepared sterile 10 mM 
hinokitiol stock in DMSO, and from a freshly prepared 10 mM FeCl3 stock in sterile water, 
respectively. Non-fermentable growth restoration used the same synthetic medium except for the 
use of 30 g/L glycerol instead of dextrose.  
 Human Caco-2 cells (HTB-37) and mouse macrophages (J774A.1) were obtained from 
ATCC and cultured with DMEM (Gibco 10313-021) containing 10% HI FBS (Gibco 16000-
036), 4 mM glutamine (Lonza BE17-605E), 100 µg/mL PEN-STREP (Lonza DE17-602E), and 
1% MEM NEAA (Fisher 11140-050). Transfected Caco-2 cell lines were maintained on this 
media containing 800 mg/L G418 (Santa Cruz sc-29065B). Friend mouse erythroleukemia cells 
(MEL, DS19 subclone) were obtained from Arthur Skoultchi (Albert Einstein College of 
Medicine, Bronx, NY) and cultured with DMEM containing 10% HI FBS, 2 mM glutamine, 100 
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µg/mL PEN-STREP, and 1% MEM NEAA. Transfected shControl and shDMT1 MEL cell lines 
were maintained on this media containing 1 g/L G418. 
 Caco-2 cells (passage 18-50) were grown in T75 flasks to ≥90% confluency before 
trypsinization with 0.25% trypsin-EDTA (Fisher 25200-056) and passaging at 10:1 dilution in 
Caco-2 media without (wild type) or with G418 (transfected). Monolayers were grown by 
seeding Caco-2 cells (passage 20-50) onto 0.4 µm PET cell culture inserts (Fisher 08-771) in 6-
well companion plates (Fisher 08-771-24) at 2x105 cells/well and allowed to fully differentiate 
for 21-28 days before experiments were performed with changing of media every 3-4 days.  
 MEL cells were grown in suspension in T25 flasks until ~1x106 cells/mL and re-seeding 
into a new T25 flask at 1x105 cells/mL in MEL Complete media with or without G418. Every 
month of culturing, new backstocks of MEL cells were used. 
 J774 cells (passage 20-80) were grown in T25 flasks to ≥90% confluency before scraping 
and re-seeding at 5:1 dilution in J774 Complete media. Media was changed every 1-2 days. 
 
Animals and animal care 
 The studies performed were in strict accordance with the guidance and recommendations 
outlined in the Guide for the Care and Use of Laboratory Animals of the National Institutes of 
Health.  
 The protocols used for studies in healthy (+/+) and Flatiron (ffe/+) mice were approved 
by the Harvard Medical Animal Care and Use Committee. Breeding, diets, and genotyping of 
flatiron mice were performed as previously described39.  
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 All zebrafish experiments were performed in accordance with the Institutional Animal 
Care and Use Committee regulations. The following wild type AB strains and zebrafish mutant 
strains were used: frascati (frstq223)42, chardonnay (cdyte216)19, and sauternes (sautb223)45. 
 The protocols for studies in Belgrade (+/+, +/b, or b/b) rats were approved by the 
Division of Laboratory Animal Medicine (DLAM) and the Northeastern University-Institutional 
Animal Care and Use Committee (NU-IACUC). Breeders of heterozygous (+/b) and 
homozygous (b/b) Belgrade rats (Fischer F344 background) were kindly provided by Dr. 
Michael Garrick (SUNY Buffalo) and maintained on a 12:12-hr light/dark cycle and given water 
and facility chow ad libitum. Prior to 59Fe gut iron absorption experiments, a variety of 
preliminary studies were performed on cohorts of Belgrade rats (ranging from 3-5 months old) 
during which the rats were treated with vehicle or various compounds for ≤ 15 weeks in iron-
supplemented diet containing 500 mg/kg iron (TD.02385, Harlan Teklad, Madison, WI). All rats 
were allowed to be drug-free and continued to receive iron-supplemented diet for at least one 
week before 59Fe gut absorption experiments were performed. 
 
Statistics 
 All data depicts the means or weighted mean ± SEM with a minimum of 3 biological 
replicates unless otherwise noted. Statistical analysis represents P values obtained from student t-
test or one- or two-way analysis of variance (ANOVA) with post-hoc TUKEY test where 






Growth rescue of iron-deficient yeast with small molecules on agar plates  
 Growth rescue in yeast was performed similar to previously reported48 on low iron SD-
agar plates in 50 mM MES/Tris buffer at pH=7.0 containing 2% agar, 10 µM FeCl3, and 10 µM 
hinokitiol (from 40X stock in DMSO). Wild type and fet3Δftr1Δ or fet3Δarn1-4Δ controls 
treated with vehicle (DMSO) were performed under identical conditions using the same low iron 
SD media containing 10 µM FeCl3 in the absence of hinokitiol. Yeast were grown overnight in 
YPD media and diluted to an optical density at 600 nM (OD600) of 1.0 in low iron SD media 
before 10-fold serial dilution and inoculation of these yeast suspensions (10 µL per dot) onto the 
low iron SD-agar plates described above containing either DMSO vehicle or hinokitiol (10 µM 
from 40X DMSO stock).  
 For disc diffusion assays, yeast were grown overnight in YPD media and diluted to an 
OD600 = 0.1 in low iron SD media and streaked onto low iron SD-agar plates containing 10 µM 
FeCl3. Disc diffusion assays were performed using ≥10 mM stock solutions (in DMSO) of 
hinokitiol, tropolone (Sigma T89702), α-dolabrin (Specs Compound Handling AN-
584/43416897), maltol (Sigma H43407), deferiprone (DFP, Sigma 379409), pyridoxal 
isonicotinoyl hydrazone (PIH, Santa Cruz sc-204192), salicylaldehyde isonicotinoyl hydrazone 
(SIH, see synthesis and characterization below), comenic acid (COMA, kindly donated by Obiter 
Research, LLC), amphotericin B (AK Scientific L970), nonactin (Sigma N2286), calcimycin 
(Sigma C7522), or prodigiosin (Santa Cruz sc-202298) (10 µL per paper disc) on low iron SD-
agar plates containing 10 µM FeCl3 streaked with the appropriate yeast strain (from OD600 = 0.1 
in low iron SD media). Growth restoration under non-fermentable conditions was performed 
using 3% glycerol instead of 2% dextrose. Images were taken 48-72 hours after inoculation and 
incubation at 30 °C unless otherwise noted. 
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Growth rescue of fet3Δftr1Δ yeast with small molecules in liquid media  
 Growth rescue in yeast was performed similar to previously reported48 using 10 µM 
hinokitiol in low iron SD liquid media containing 10 µM FeCl3 in a 96-well plate unless 
otherwise noted. Wild type and fet3Δftr1Δ controls treated with vehicle (DMSO) were 
performed under identical conditions using the same low iron SD media containing 10 µM FeCl3 
in the absence of hinokitiol. Yeast were grown overnight in YPD media and diluted at an OD600 
of 0.1 in SD media, diluted 10-fold, and incubated at 30 °C with continuous shaking (200 rpm). 
The OD600 was obtained 24-48 hours after inoculation unless otherwise noted.  
 Small molecule dose-response with hinokitiol and C2-deoxy hinokitiol (C2deOHino, see 
synthesis below) was determined by addition of the small molecule (40X stock solution in 
DMSO) to give the indicated final concentrations.  
 Iron dose-response studies were performed in the same low iron SD media without FeCl3 
containing 10 µM hinokitiol (from a 40X stock solution in DMSO). FeCl3 (40X stock solution in 
water) was added to the give the indicated final concentrations up to 10 µM FeCl3.  
 For dose-dependent hinokitiol-promoted rescue at increasing dosages of FeCl3 , SD 
media was made containing either 10, 25, 50, or 100 µM FeCl3 from a 10 mM FeCl3 stock before 
adding hinokitiol (40X stock solution in DMSO) to give the indicated final concentrations. 
 
Sustainability assay 
 Sustainable hinokitiol-promoted growth restoration of fet3Δftr1Δ yeast was performed 
similar to previously reported48 by inoculation of hinokitiol-rescued yeast from low iron SD-agar 
plates containing 10 µM hinokitiol and 10 µM FeCl3 into low iron SD liquid media containing 
10 µM hinokitiol and 10 µM FeCl3, then streaking of the yeast suspension (diluted to OD600 of 
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0.1) onto agar plates. This process was repeated for >100 days. Continued reliance of fet3Δftr1Δ 
yeast growth on hinokitiol was observed, as removal of hinokitiol from the SD-agar plates led to 
no fet3Δftr1Δ yeast cell growth. 
 
Doubling time of fet3Δftr1Δ yeast treated with hinokitiol  
 Doubling times of wild type and hinokitiol-rescued fet3Δftr1Δ yeast were determined 
similar to previously reported48 by tracking the OD600 every hour over 48 hours in the same low 
iron SD media containing 10 µM FeCl3 and DMSO or 10 µM hinokitiol (from 40X stock in 
DMSO) and applying the equation Td = (t2-t1) x [log(2)/log(q2/q1)] during exponential phase. 
 
55Fe3+ uptake assay in yeast  
 Iron (III) uptake into wild type and fet3Δftr1Δ yeast was adapted from Kosman and 
coworkers46. Overnight yeast cultures were repeatedly centrifuged and rinsed with water. The 
cell pellet was resuspended in MilliQ water, and diluted in SD media without FeCl3. The cells 
were incubated at 30 °C for 3 hours, centrifuged and rinsed with water twice. The cells were then 
suspended to 3x107 cells/mL in SD media containing 50 mM sodium citrate and 2% glucose. 
Hinokitiol or C2deOHino (from 40X stocks in DMSO) was added to a final concentration of 100 
µM before 55FeCl3 (1.1 µCi) was added to the yeast suspensions. The suspension was 
continuously homogenized before aliquots were taken and diluted with 10 mL of room 
temperature water. Cells were then collected via vacuum filtration through a 0.45 µm 
nitrocellulose filter (Millipore HAWP), and rinsed with room temperature water (x5 of 100mL). 
The filters were then transferred to a scintillation vial containing 3 mL of scintillation cocktail 
for measuring radioactivity using a liquid scintillation counter. Hinokitiol showed a dose-
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dependent increase in 55Fe uptake from 5 to 100 µM while C2deOHino showed no uptake up to 
100 µM. 
 
Lipophilicity determination for small molecule iron chelates 
 Octanol-water partition coefficients were obtained as previously reported49,50 with 100 
µM small molecule and 33 µM FeCl3, (50 µM FeCl3 for PIH as it forms a 2:1 complex) using 
equal volumes of equilibrated pH=5 water and octanol. Concentrations of small molecule in 
water were determined via UV-Vis spectroscopy compared to known initial standards. 
 Hexane-water partition was obtained similar to above with 500 µM small molecule and 
50 µM FeCl3 using equal volumes of 50 mM Mes-Tris buffer at pH=7.0 and hexanes. 
 
Titration of hinokitiol with iron (III)  
 An iron (III) titration study was performed by addition of 50 µM hinokitiol and 
increasing equivalents of FeCl3 (0, 1, 5, 10, 12.5, 15, 16.67, 17.5, 20, 25, 30, 35, 37.5, 40, and 50 
µM) in 10 mM MES/Tris buffer at pH=7.0. No precipitate was observed in all cases, and the 
solution changed to a brown colored solution with increasing equivalents of iron (III). As the 
amount of iron was increased, the λmax shifted from ~240 to 250 nm and the absorbance at 420 
nm increased up to ~3:1 Hino:Fe. 
 
Crystal structure of Fe(Hino)3  
 An x-ray quality crystal of synthesized Fe(Hino)3 was obtained from a recrystallization of 
Fe(Hino)3 (10 mg) in acetone (2 mL) and benzene (0.2 mL) in an uncapped 1 mL vial by 
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allowing the solvent to slowly evaporate undisturbed overnight. X-Ray single crystal analysis 
was performed by the University of Illinois X-Ray facility. 
 
Determination of iron efflux from liposomes using ferrozine 
 Iron (III) efflux from POPC liposomes was determined similar to previously reported51. 
POPC liposomes were prepared as similarly reported52 using 30 mM FeCl3, 62.5 mM citrate at 
pH=7.0 in 25 mM Mes/Tris buffer. External iron was removed by size exclusion 
chromatography using Sephadex G-50 and eluting with external buffer. External buffer consisted 
of 62.5 mM ascorbate at pH=7.0 in 25 mM Mes/Tris buffer. The liposomes were diluted to 1 
mM phosphorus in this buffer. Ferrozine (Sigma 160601) was added (100X stock in external 
buffer) to a final concentration of 500 µM. Liposomal suspension was then transferred to a 96-
well plate, and either DMSO or 5 µM hinokitiol, C2deOHino, deferiprone, or PIH (40X stock 
solution in DMSO) were added to initiate the experiment. The OD562 was determined every 
minute over the course of 2 hours using a plate-reader with continuous shaking at 30 °C to detect 
the relative amounts of external ferrozine-iron chelate at the indicated times. After 2 hours, 
liposomes were lysed with Triton-X to give 100% iron efflux. Hinokitiol dose- and temperature-
dependently promoted iron (III) efflux from POPC liposomes while C2deOHino showed no 
efflux up to 100 µM. 
 Iron (II) efflux was performed as described above, however, the internal buffer 
alternatively consisted of 30 mM FeSO4, 62.5 mM ascorbate at pH=7.0 in 25 mM Mes/Tris 
buffer and Triton-X lysis was performed after 1 hour. 
 The rates of iron efflux with increasing concentrations of intraliposomal iron and/or 
hinokitiol were determined as described above using the indicated concentration of iron and 
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hinokitiol. For the varying concentrations of iron, hinokitiol (10 µM) was added to the POPC 
liposomes, and the change in absorbance at 562 nm was determined over 2 hours. For the 
varying concentrations of hinokitiol, 30 mM intraliposomal iron was used as described above. 
The concentration of iron outside of liposomes was determined using the extinction coefficient 
for ferrozine-iron (27,900 M-1cm-1)53. This was used to determine the amount of iron released 
from liposomes at the indicated times using the total volume for each experiment. Rates of iron 
efflux were determined after one hour of hinokitiol treatment. 
 
Determination of metal efflux from liposomes using PhenGreen  
 Hinokitiol-promoted release of different divalent metals from POPC liposomes was 
performed by tracking the quenching of PhenGreen (Fisher P14312) similar to previously 
reported54,55. Liposomes were prepared as described above with an internal buffer consisting of 
either 10 mM ascorbate in a 5 mM MES/Tris buffer at pH=7.0 (for Fe2+), 10 mM citrate in a 5 
mM MES/Tris buffer at pH=7.0 (for Cu2+), or a 5 mM MES/Tris buffer at pH=7.0 (for Mn2+, 
Co2+, Ni2+, and Zn2+). In all cases, liposomes were prepared using 5 mM of either FeCl2, MnCl2, 
CoCl2, NiCl2, ZnCl2, or CuCl2 added to the internal buffer. The external buffer was a 5 mM 
MES/Tris buffer at pH=7.0 containing 10 µM PhenGreen (from 1000X stock in DMSO). The 
liposome suspension was diluted to 1 mM of phosphorus. The liposome suspension was 
transferred to a 96-well plate, and either DMSO or 2 µM hinokitiol (from a 40X stock in DMSO) 
was added at t = 2min. The fluorescence was monitored with excitation at 500 nm and emission 
at 530 nm over 1 hour. After one hour, the liposomes were lysed with Triton-X and the 
fluorescence was recorded. In all cases, quenching of fluorescence was observed in the DMSO-
treated liposomes after lysis, which reached similar levels to that for hinokitiol-treated liposomes 
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before lysis (except for Mn2+ where no efflux was observed in Hino-treated liposomes; 
fluorescence quenching was observed after lysis for Mn2+). The DMSO-treated and hinokitiol-
treated liposomes had similar fluorescence quenching levels after lysis. The total amount of 
metal efflux was determined using standard curves of fluorescence quenching in external buffer 
with 10 µM PhenGreen and known concentrations of each metal. The t1/2 values were calculated 
using an asymptotic fit in OriginPro. The t1/2 values indicate the time required to reach half of the 
maximum metal efflux for each metal. 
 
Transfection of Caco-2 cells and MEL cells against DMT1 
 Caco-2 cells were transfected as previously reported18 using lipofectamine LTX 
(Invitrogen 15338-100) and Plus reagent (Invitrogen 11514-015) with 10 µg/well of either non-
targeting control shRNA or four other shRNA constructs targeting human DMT1 (Qiagen 
KH05760N) 24 hours after seeding 2x105 cells/well in 6-well plates (~30% confluent). The 
transfection agents were removed, and the cells were allowed to recover for 24 hours before 
treatment with Caco-2 Complete media containing 0.8 g/L G418. Cells were incubated in G418 
media for ~2 weeks to promote selection of transfected cells while complete cell death was 
observed with non-transfected cells. Non-targeting control construct = 5’-
GGAATCTCATTCGATGCATAC-3’; shDMT1 construct (Clone 4) = 5’-
AACCTATTCTGGCCAGTTTGT-3’. 
 MEL cells were transfected by electroporation (0.28 kV, 975 µF pulse) in 0.4 cm cuvette 
(Biorad 1652081) containing 400 µL of serum-free DMEM with 30 mM NaCl at 2x107 cells/mL 
with 50 µg of either non-targeting control shRNA (Sigma, 5’-
CAACAAGATGAAGAGCACCAA-3’ using a CMV-neo vector) or five shRNA constructs 
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targeting mouse DMT1 (Sigma, Clone 1-5: TRCN0000332748, TRCN0000306610, 
TRCN0000079533, TRCN0000079535, and TRCN0000079536). After transfection, cells were 
transferred to T25 flasks containing 10 mL of MEL Complete media, and allowed to grow for 6 
days with re-seeding every 2 days at 10:1 dilution in fresh MEL Complete media. After this, 
cells were re-seeded at 1x105 cells/mL in MEL Complete media containing 1 g/L G418, and cells 
were selected over the course of 2 weeks by re-seeding at 10:1 dilution into fresh G418 media 
every ~2 days until no cells were observed in T25 flasks originally containing non-electroporated 
wild type (DS19) MEL cells.  
 Mfrn1-deficient MEL cell lines were developed using CRISPR/Cas9 genome editing as 
previously described56–58. Exons 2 and 4 of the Mfrn1 locus were targeted. The exon 2 targeting 
sequence was: 5’-GATGCTTGTATACCGGGCTT-3’; the exon 4 targeting sequence was: 5’-
GAAGAACTCATAAACGGACC-3’. The primers used for documenting intragenic deletion of 
the Mfrn1 mouse locus were the following: Exon 4 (Fwd) 5’-GTTTGCCTCTGCGGTGTGATC-
3’; Exon 2 (Fwd) 5’-GGAGGACGCTGTGGGGGGGGG-3’; Exon 2 (Rev) 5’-
GTCCATCTTTTCTACAAGCC-3’. 
 
qRT-PCR conditions  
 Dmt1 mRNA levels were determined via qRT-PCR using SYBR Green (Agilent 600825) 
following manufacturer protocols after undergoing treatment as described below. For 
determination of Dmt1 mRNA levels in differentiated Caco-2 monolayers (21-28 days post 
seeding), mRNA was isolated using RNeasy Mini Kit (Qiagen 74104) according to manufacturer 
instructions. The threshold cycle (Ct) values of Dmt1 were normalized to internal control actin 
	
	 60	
using primers against Dmt1 (Origene HP200584) and actin (Origene HP204660) using the Pfaffl 
Method and were then normalized to shControl levels.  
 For determination of relative Dmt1 mRNA levels in MEL clones, mRNA was isolated 
from MEL clones differentiated with 2% DMSO and 10 µM iron (III) citrate for 3 days using 
RNeasy Mini Kit (Qiagen 74104) according to manufacturer instructions. The Ct values of Dmt1 
were normalized to internal control Hprt1 using primers against Dmt1 (Origene MP215650) and 
Hprt1 (Origene MP206455) using the Pfaffl Method and were then normalized to shControl 
levels.  
 Relative Mfrn1 mRNA levels were determined via qRT-PCR using TaqMan probes 
(Applied Biosystems) as previously described59. 
 
Western blotting conditions  
 Caco-2 monolayers, differentiated MEL cells, or J774 cells underwent treatment as 
described in rescue experiments before lysis with RIPA buffer (Thermo 89901) containing 
protease inhibitors (Thermo 88266). Protein concentrations were determined by a BCA kit 
(Thermo 23225) and diluted to 2 mg/mL in the same RIPA buffer. Relative protein levels were 
then determined through western blotting of 10 or 20 µg of protein lysate blocking for 2 hours at 
room temperature with 5% BSA and using primary antibodies consisting of either human anti-
DMT1 (1:3,000 dilution, Santa Cruz sc-30120), mouse anti-DMT1 (1:1,000 dilution, Santa Cruz 
sc-166884), in 5% BSA overnight at 5 °C before rinsing thoroughly with TBST and incubation 
(if non-HRP conjugated) with secondary antibody consisting of either goat anti-rabbit IgG HRP 
conjugate (1:5,000 dilution – DMT1, Cell Signaling 7074, in 5% milk), goat anti-mouse IgG1 
HRP conjugate (1:1,000 dilution – PCBP1, 1:5,000 dilution – IRP2, 1:3,000 dilution – DMT1, 
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Santa Cruz sc-2060, in 5% BSA), donkey anti-goat IgG HRP conjugate (1:1,000 dilution – IRP1, 
Santa Cruz sc-2020, in 5% BSA), or goat anti-mouse IgG2a HRP conjugate (1:10,000 dilution – 
FTL1, Santa Cruz sc-2061, in 5% BSA) at room temperature for two hours. Blots were 
thoroughly rinsed with TBST and imaged after addition of Femto Chemluminescence solution 
according to manufacturer instructions (Thermo Fisher 34095).  
 
55Fe uptake and transport in differentiated Caco-2 monolayers 
 Media from differentiated Caco-2 monolayers (P25-50, 21-28 days post seeding) grown 
on PET inserts in 6-well plates was aspirated, and monolayers were rinsed with PBS. 2 mL of 
basolateral fluid (serum-free DMEM at pH = 7.4 in 10 mM HEPES buffer) was added to the 
basolateral side, and 1 mL of apical fluid (serum-free DMEM at pH = 5.5 in 10 mM MES buffer) 
containing 200 nM 55FeCl3 or the indicated concentration of FeCl3 and either DMSO vehicle, 
hinokitiol, C2deOHino, deferiprone, PIH, SIH, or deferoxamine mesylate (Sigma D9533) (500 
nM Hino/C2deOHino for DMT1-deficiency, 1 µM Hino/C2deOHino for FPN1-deficiency, or 
indicated concentration of small molecule from a 1000X stock in DMSO) was added to the 
apical side via addition on the wall of the membrane insert without disrupting the cell monolayer. 
The monolayers were then incubated for four hours at 37 °C unless otherwise noted. A 100 µL 
aliquot of the basolateral fluid was removed, diluted in scintillation cocktail, and radioactivity 
was determined on a liquid scintillation counter to quantify relative amounts of 55Fe transport. To 
determine intracellular 55Fe, the basolateral and apical media was removed, and the monolayer 
was rinsed with PBS (x2). The cells were then lysed with 500 µL of 200 mM NaOH with nutator 
mixing overnight, and radioactivity was determined on a liquid scintillation counter after diluting 
the cell lysate in scintillation cocktail. All values were normalized to shControl monolayers 
unless otherwise noted. Absolute iron levels were determined through calibration of 55Fe 
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radioactivity levels with known standards and average mg of protein per membrane was 
determined by protein lysis with RIPA buffer containing protease inhibitors and quantified 
through a BCA kit according to manufacturer instructions.  
 Determination of 55Fe transport as a function of pH used the protocol described above 
except for the use of apical fluid containing either 10 mM PIPES (pH=6.5) or 10 mM HEPES 
(pH=7.4) in DMEM.  
 Determination of 55Fe transport after FPN1 knockdown was determined as described 
above using 200 nM 55FeCl3 after incubation of quercetin to knockdown FPN129 as described 
below. 
 
TEER determination in Caco-2 monolayers  
 To determine Caco-2 membrane integrity, transport studies were performed as described 
above, except for the use of non-radioactive iron instead of 55FeCl3. At the indicated time points, 
the transepithelial electrical resistance (TEER) was determined with an epithelial voltohmmeter 
and compared to the TEER of the membrane at the beginning of the experiment. 
 
WST-8 toxicity in cell lines  
 Determination of small molecule-mediated toxicity in Caco-2, MEL, and/or J774 cells 
was performed according to manufacturer instructions using a WST-8 kit (Cayman Chemical 
10010199) similar to previously reported60 using a 1000X stock of the indicated small molecule 





Differentiation of MEL cells with DMSO  
 To perform differentiation experiments with MEL cells24f, the indicated MEL cells were 
diluted to 1x105 cells/mL in MEL Complete media containing 10 µM iron (III) citrate and 2% 
DMSO in the absence or presence of 1 µM hinokitiol or C2deOHino (added from 1000X stock 
in DMSO) in 12-well plates. Cells were then incubated at 37 °C for 72 hours unless otherwise 
noted. Control experiments were performed under identical conditions in the absence of DMSO, 
and it was found that no differentiation was observed by o-dianisidine staining as described 
below. 
 
Staining of induced MEL cells with dianisidine  
 Hemoglobinized MEL cells were quantified three days after DMSO induction through o-
dianisidine staining similar to previously reported58. Cells were centrifuged three days after 
induction and rinsed with PBS. The cells were then suspended in a solution containing 7.5 mM 
o-dianisidine, 900 mM H2O2, and 150 mM acetic acid in water at ~1x106 cells/mL. Cells were 
then imaged on an AXIO Zoom V16 microscope to obtain color images. The number of stained 
cells were then quantified via ImageJ analysis and compared to the number of total cells in each 
image. To determine that hinokitiol requires DMSO induction for hemoglobinization, 2% DMSO 
was not added at the beginning of the experiment before a 72-hour incubation and o-dianisidine 
staining. 
 
55Fe heme incorporation in MEL cells  
 MEL cells were induced for differentiation as described above and incubated at 37°C for 
64 hours before addition of a saturated 55Fe2Tf solution (250 nM final concentration from a 10 
µM 55Fe2Tf stock). The cells were incubated for an additional eight hours. After completion, the 
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cells were counted with a hemocytometer, the media was removed after centrifugation, and the 
cells were rinsed with PBS (x3). The cells were then lysed with RIPA buffer, diluted with water, 
and heme was extracted using a 3:1 ethyl acetate:acetic acid solution. An aliquot of the organic 
extract was diluted in scintillation cocktail and radioactivity was determined. Radioactive levels 
were normalized per cell (counted by hemocytometer) relative to wild type (DS19) levels. 
 
Knockdown of FPN1 in Caco-2 cells and J774 cells  
 To knockdown FPN1 levels in wild type Caco-2 cells, the differentiated epithelial 
monolayers were incubated with 150 µM quercetin (Sigma 337951) for 18 hours in Caco-2 
Complete media containing G418 similar to previously described29. To knockdown FPN1 levels 
in shControl and shDMT1 Caco-2 monolayers, incubation was performed as above except with 
250 µM quercetin. After completion of the incubation, the apical and basolateral fluid was 
aspirated and rinsed with PBS before 55Fe transport and uptake were determined as described 
above. 
 To knockdown FPN1 levels in wild type J774 cells, the cells were incubated with 2 
µg/mL mouse hepcidin (Peptides International PLP-3773-PI) for 1 hour in J774 Complete media 
similar to previously described35 before 55Fe was loaded into J774 cells and 55Fe release was 
determined. 
 
55Fe release from J774 macrophages 
 J774 cells were grown in 12-well plates to ~80% confluency. The cells were then treated 
with vehicle or hepcidin in fresh J774 Complete media (1 mL) and incubated at 37 °C for 1 hour. 
After incubation, the media was aspirated, and then a 55Fe2Tf (50 nM) solution in J774 Complete 
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media (1 mL) containing vehicle or hepcidin was added. The cells were incubated at 37 °C for 10 
minutes, and the media was removed. The cells were rinsed with PBS (x2), and then rinsed with 
J774 Complete media (1 mL) for 10 minutes at 37 °C. The media was aspirated, and J774 
Complete media (1 mL) containing DMSO or small molecule (5 µM unless otherwise noted, 
1000X dilution) was then added in the presence or absence of hepcidin. At the indicated times, 
aliquots (≤ 100 µL) of the media were removed, diluted in scintillation cocktail, and radioactivity 
was determined by liquid scintillation counting. After completion of the experiment, the media 
was removed, the cells were rinsed with PBS, and the cells were lysed with 500 µL of 200 mM 
NaOH at 37 °C for 2 hours with continuous shaking (50 rpm). The cell lysate was diluted in 
scintillation cocktail and intracellular 55Fe levels were determined by liquid scintillation 
counting. The % 55Fe release was determined by the ratio of extracellular 55Fe to total 
(intracellular + extracellular) 55Fe at the indicated times. 
 
55Fe uptake into J774 macrophages  
 J774 cells were grown in 12-well plates to ~80% confluency. The cells were then treated 
with vehicle or hepcidin in serum-free DMEM media at pH=7.4 in 10 mM HEPES buffer (1 mL) 
containing 50 µM FeCl3 (100:1 56Fe:55Fe). After four hours of incubation at 37 °C, the cells were 
rinsed with PBS (x2), and lysed with 500 µL RIPA buffer containing protease inhibitors. The 
cell lysate was diluted in scintillation cocktail and intracellular 55Fe was determined by liquid 
scintillation counting and normalized to the total protein in each well. 
 Hinokitiol-promoted iron uptake as a function of extracellular iron was performed similar 
to described above in wild type J774 macrophages using 1 µM hinokitiol (from 1000X stock in 
DMSO) and the indicated final concentration of FeCl3 (20:1 56Fe:55Fe). At the indicated time, 
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cells were rinsed with PBS (x2), and lysed with 200 mM NaOH. The cell lysate was diluted in 
scintillation cocktail and intracellular 55Fe was determined by liquid scintillation counting and 
normalized to the total protein in each well. 
 
59Fe gut absorption  
 To characterize the effects of hinokitiol on the gastrointestinal absorption of iron in 
healthy (+/+) and ffe/+ mice, food was withheld for 4 hours (8am to 12pm) prior to intragastric 
gavage. The mice were anesthetized with up to 2% isoflurane, and 59FeCl3 was administered 
using a 20-gauge, 1.5-inch gavage needle. 59FeCl3 (200 µCi/kg body weight) was diluted in Tris-
buffered saline containing 10 mM ascorbic acid in the presence or absence of 6 mM hinokitiol. 
Final volume administered was 1.5 mL/kg for each mouse, correcting for individual body 
weight. Blood was collected at 60, 120, and 240 min after administration to determine 59Fe 
levels. Mice were humanely sacrificed by isoflurane overdose after 6 hours and blood was 
collected by cardiac puncture. Radioactivity was quantified by gamma counting and calculated 
as the percentage of gavaged dose (± SEM). Experiments were performed with 4 genotyped-
matched mice/day; preliminary analysis determined there were no gender effects on uptake of 
59Fe after intragastric gavage; mixed genders were used in the experiments shown. 
 59Fe gastrointestinal absorption of iron in 3-5-month-old b/b rats was characterized 
similar to the procedure described above in the presence of either 6 mM hinokitiol or 6 mM 
C2deOHino. To compare with the rate of normal iron uptake, age-matched sibling control (+/+ 
or +/b) Belgrade rats were tested by the same procedure except that 59Fe was administered 
without small molecule. Blood (50 µL) was taken from the tail vein at 15, 30, 60, 120, 180, 240, 
and 360 minutes post administration. Radioactivity was quantified by gamma counting and 
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calculated as the percentage of gavaged dose (± SEM). Animals were humanely euthanized at 6 
hours. 
 
Knockdown in morphant zebrafish  
 The morpholinos (MOs) were purchased from GeneTools, LLC (Philomath, OR). The 
sequences of the MO used were as follows: dmt1 MO: 5’-
GAGTGTGAAACGTGACGCACCCCTT-3’; mfrn1 MO: 5’-
TAAGTTGCATTACCTTGACTGAATC-3’. Zebrafish embryos at the 1-cell stage were injected 
with MOs as previously described56,61. o-dianisidine staining for hemoglobinized cells in 
embryos was as previously described62. Quantification by flow cytometry using fluorescently 
labeled erythrocytes from the transgenic Tg(globinLCR:eGFP) line43 was performed as 
previously described56,59. Semi-quantitative RT-PCR of dmt1 mRNA in morphants was 
performed using custom designed probes as previously described63. The sequences of the dmt1 
primers are as follows: 5’-CTGAACCTGCGCTGGTCCC-3’ (Fwd); 5’-
TCCGTTAGCGAAGTCGTGCATG-3’ (Rev). The sequences of the control actb primers were 
as follows: 5’-GTTGGTATGGGACAGAAAGACAG-3’ (Fwd); 5’-
ACCAGAGGCATACAGGGACAG-3’ (Rev).  
 
Restored hemoglobinization in transporter-deficient zebrafish  
 Either mutant or morphant embryos were allowed to develop to >24 hours post 
fertilization (hpf), then dechorionated with pronase as previously described64.  The dechorionated 
embryos or morphants were then incubated in the presence of 1 µM hinokitiol (or vehicle) and 
10 µM iron (III) citrate for an additional forty-eight hours. Vehicle treated embryos were 
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exposed to 0.01 mM DMSO. C2deOHino (1 µM) with iron (III) citrate (10 µM) was used as a 
negative control. Control and either mutant or morphant embryos at ~72 hpf were either (a) 
directly stained by o-dianisidine62a or (b) mechanically homogenized as previously described for 
flow cytometry59,61.   
 
Genotyping and imaging of mutant zebrafish from heterozygous cross 
 Genotyping of the hinokitiol-rescued frstq223 embryos were performed as previously 
described42.  
 
Synthesis and Characterization of Small Molecules 
Materials 
Commercial reagents were purchased from Sigma-Aldrich and were used without further 
purification unless otherwise noted. Solvents were purified via passage through packed columns 
as described by Pangborn and coworkers65. All water was deionized prior to use.  
 
General experimental procedures 
 Unless otherwise noted, reactions were performed in flame-dried round-bottomed or 
modified Schlenk flasks fitted with rubber septa under a positive pressure of argon. Organic 
solutions were concentrated via rotary evaporation under reduced pressure with a bath 
temperature of 20-35 °C unless otherwise noted. Reactions were monitored by analytical thin 
layer chromatography (TLC) using the indicated solvent on E. Merck silica gel 60 F254 plates 
(0.25 mm). Compounds were visualized by exposure to a UV lamp (λ = 254 nm or 366 nm), 
and/or a solution of KMnO4 stain, followed by heating using a Varitemp heat gun. Flash column 
	
	 69	
chromatography was performed using Merck silica gel grade 9385 60Å (230-240 mesh). 
Preparative HPLC purification was performed using an Agilent 1260 Infinity series preparative 
HPLC with a SunFire 5 µm C18 column (Waters Corporation). 
 
Structural analysis  
 1H NMR, 13C NMR, and 19F NMR were recorded at 20 °C on Unity Inova 500NB, 
Varian XR500, or Unity 500 instruments. Chemical shifts (δ) are reported in parts per million 
(ppm) downfield from tetramethylsilane and referenced to residual protium in the NMR solvent 
(CHCl3, δ=7.26; DMSO-d6, δ=2.50). Data are reported as follows: chemical shift, multiplicity 
(s=singlet, d=doublet, t=triplet, m=multiplet, app=apparent), coupling constant (J) in Hertz (Hz), 
and integration. 13C NMR are referenced to carbon resonances in the NMR solvent (CDCl3, 
δ=77.16; DMSO-d6, δ=39.52). 19F NMR are referenced to fluorine resonance in an external 
standard (CFCl3, δ=0.00) High resolution mass spectra (HRMS) were performed at the 
University of Illinois, School of Chemical Sciences Mass Spectrometry Laboratory. Elemental 
analysis was performed at the University of Illinois Microanalysis Laboratory. HPLC 
characterization was performed using an Agilent 1260 Infinity series analytical HPLC with a 5 









Iron (III) hinokitiol complex  
 
To a flame-dried 20-mL vial equipped with a stir bar was added iron (III) nitrate nonahydrate 
(819.8 mg, 2.03 mmol) followed by hinokitiol (1.0092 g, 6.15 mmol). Then ethanol (10 mL) was 
added. The reaction was vigorously stirred for 2 hours to give a purple colored suspension. The 
product was collected via filtration and recrystallized in acetone to yield the product as a purple 
solid (959.9 mg, 1.76 mmol, 86.7% yield). 
 
HRMS (ESI+) 
 Calculated for C30H34O6Fe (M+H)+ : 546.1705 
 Observed : 546.1703 
Elemental Analysis 
 Calculated [C]  : 66.06% Observed [C]  : 65.88% 
 Calculated [H]  :   6.10% Observed [H]  :   6.21% 






Triflation of hinokitiol  
 
 
To an oven-dried 300 mL round-bottomed flask equipped with a stir bar was added hinokitiol 
(3.014 g, 18.27 mmol) followed by anhydrous CH2Cl2 (200 mL). The system was put under 
nitrogen, and freshly distilled lutidine (2.54 mL, 21.92 mmol) was added via syringe. The system 
was cooled to 0 °C in an ice/water bath before triflic anhydride (3.38 mL, 20.10 mmol) was 
added dropwise via syringe. The solution was stirred for 15 minutes at 0 °C, then allowed to 
warm to room temperature and stirred for an additional 3 hours. After completion, the reaction 
was quenched with a saturated aqueous NH4Cl solution. The product was extracted in CH2Cl2, 
washed with CuSO4, washed with brine, and dried over anhydrous MgSO4. The product was 
filtered and solvent removed by rotary evaporation. The product was then purified as an 
inseparable mixture of the C-2 and C-7 isomers by flash column chromatography (3:1 
Hexane:EtOAc) to yield a slightly colored oil (4.819 g, 16.27 mmol, 88.6% yield as a 53:47 
mixture of the C-2 and C-7 isomers). 
TLC (1:1 Hex:EtOAc) 
 Rf = 0.68, visualized by UV (254 nm) and KMnO4 stain 
H NMR (500 MHz, CDCl3) 
 δ 7.34-7.24 (m, 5H), 7.14 (dt, J = 11.5, 0.7 Hz, 1H), 7.08 (dt, J = 8.6, 0.6 Hz, 1H), 6.99 
 (dd, J = 11.4, 9.4 Hz,  1H), 2.91-2.80 (app. m, 2H), 1.26 (d, J = 6.8 Hz, 6H), 1.26 (d, J = 





13C NMR (126 MHz, CDCl3) 
 δ 178.0, 177.7, 158.7, 155.9, 152.3, 139.0, 138.2, 137.9, 137.8, 131.9, 129.9, 129.3, 
 127.6, 38.8, 38.2, 22.9, 2.8 
19F NMR (470.2 MHz, CDCl3) 
 δ -74.76, -74.84 
HRMS (ESI+) 
 Calculated for C11H12F3O4S (M+H)+ : 297.0408 
 Observed    : 297.0408 
 




Sodium acetate (1.11 g, 13.4 mmol), the triflated hinokitiol (2.00 g, 6.76 mmol), 10 wt% 
palladium on carbon (71.8 mg) and methanol (75 mL) were added to a flame-dried 200 mL 
round-bottomed flask containing a stir bar. The suspension was degassed with N2, then put under 
a H2 atmosphere without bubbling H2 through the solution. The reaction was stirred and analyzed 
by TLC (Et2O) for 30 minutes. After completion, N2 was bubbled through the system, and the 
black suspension was filtered over celite. The methanol was removed by rotary evaporation, and 




MgSO4, the solvent was removed by rotary evaporation to yield a slightly colored oil. The 
product was purified by preparative HPLC (283 nm, 20% MeCN in H2O) to yield C2-
deoxyhinokitiol and C7-deoxyhinokitiol as clear oils (C2deOHino: 325 mg, 2.21 mmol, 32.4% 
yield; C7deOHino: 204 mg, 1.38 mmol, 20.4% yield). 
 
TLC (Et2O) 
 Rf = 0.49, visualized by UV (254 nm) and KMnO4 stain 
1H NMR (500 MHz, CDCl3) 
 δ C2: 7.10-6.97 (m, 3H), 6.91 (ddd, J = 12.0, 2.6, 0.8 Hz, 1H), 6.81 (ddd, J = 8.7, 1.5, 0.7 
 Hz, 1H), 2.73 (heptet, J = 6.8 Hz, 1H), 1.19 (d, J = 6.9 Hz, 6H) 
 δ C7: 7.09-7.01 (m, 3H), 6.93-6.92 (m, 2H), 2.74 (heptet, J = 6.8 Hz, 1H), 1.21 (d, J = 
 6.9 Hz, 6H) 
13C NMR (126 MHz, CDCl3) 
 δ C2: 188.0, 156.2, 141.9, 140.1, 138.1, 137.2, 130.5, 38.1, 23.0 
 δ C7: 188.0, 157.4, 141.9, 138.7, 137.1, 136.1, 133.8, 38.4, 22.9 
HRMS (ESI+) 
 Calculated for C10H13O (M+H)+   : 149.0966 
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HINOKITIOL HARNESSES IRON GRADITENTS THAT ACCUMULATE IN IRON 
TRANSPORTER DEFICIENT SYSTEMS 
 
3.1 INTRODUCTION  
 In the previous chapters I have demonstrated that hinokitiol, a lipophilic, iron binding 
small molecule can transport iron across lipid membranes as well as mobilize iron into, within 
and out of living cells thus restoring physiology in iron transporter deficient cellular and animal 
models. With all of the phenomenological data in hand we next wanted to understand how an 
imperfect small molecule that has no inherent direction specificity on its own was restoring iron 
movement in site- and direction-specific ways. Hinokitiol did not appear to be moving iron or 
other metals out of cellular compartments when it was unhelpful or even pathological, as 
evidence by the lack of toxicity in most cell lines as well as animal models. We thus 
hypothesized that in the absence of an iron transporting protein a build up of iron would occur 
upstream of the missing protein because all of the other drivers of iron transport, iron 
transporters as well as other ion pumps and channels would be active. We hypothesized that 
these pumps and channels would be upregulated in order to compensate for the missing iron 
transporter1,2, therefore priming the system for unidirectional iron movement. If logic followed 
these gradients would then allow a relatively non-selective small molecule, such as  hinokitiol, to 
simply act as a shuttle, moving the iron down the gradient according to diffusion and Le 
Chatelier's principle.  
 Portions of the work presented in this chapter were preformed with aid from my 
colleagues Dr. Anthony Grillo, Dr. Alexander Cioffi. Portions of this chapter have been adapted 
from Grillo, A. S.; SantaMaria A. M.; Kafina M. D.; Cioffi A.G.; Huston N. C.; Han M.; Seo Y. 
A.; Yien Y.Y.; Nardone C.; Menon A. V.; Fan J.; Svoboda D. C.; Anderson J. B.; Hong J.D.; 
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Nicolau B. G.; Subedi K.; Gewirth A. A.; Wessling-Resnick M.; Kim J.; Paw B. H.; Burke M. D. 
“Restored iron transport by a small molecule promotes absorption and hemoglobinization in 
animals” Science. 2017, 356, 608-616. Reprinted with permission from AAAS. 
 
3.2 SITE- AND DIRECTION-SELECTIVE BUILDUP OF IRON GRADIENTS AND 
RELEASE WITH HINOKITIOL 
 We hypothesized that there was a site- and direction-selective build up in iron transporter 
deficient cells, upstream of the missing protein (Figure 1.5). Further, we hypothesized that this 
gradient is what was allowing hinokitiol to restore iron movement into, within and out our 
multiple models of iron transporter deficiency (Figure 1.6). Therefore we set out to test this 
hypothesis.   
 In order to see where the iron was 
located in our cells in real time we chose to 
use temporal, confocal, fluorescent 
microscopy with iron binding dyes that 
localized to specific locations within the 
cell. In the DMT1 deficient MEL cells the 
iron gradient we predicted was expected to 
be in the endosome making DMT1 deficient 
cells a great candidate for study. Because the 
gradients as well as their target location are all housed within the cell, we could watch were the 
iron was going within a cell with different treatment groups (Figure 3.1 A and B). In order to 
visualize the iron pools within the DMT1-deficient MEL cells we chose fluorescent dyes that 
localized to specific cellular locations (Figure 3.2 A-C)3–5. We chose to use an oxyburst green-
protein	deficiency	
+	small	molecule	
Figure 3.1 shDMT1 MEL cells with an iron 
gradient in their late endosome being 
released by hinokitiol 
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BSA conjugate that localizes to endosomes and fluoresces upon iron-mediated oxidation (Figure 
3.2 C), and fluorescence emissions from the turn-off probes calcein green (Figure 3.2 A) which 
localizes to the cytosol and is quenched when iron binds and RPA (Figure 3.2 B) which 
localizes to the mitochondria and is likewise quenched upon iron binding.  
  
 Relatively low endosomal, high cytosolic, and high mitochondrial iron levels were 
observed in induced shControl MEL cells (Figure 3.3 A-D) We observed 2-fold increases in 























Figure 3.2 Use of iron-sensitive fluorescent dyes to visualize intracellular iron 
levels. (A and B) Structures of turn-off probes (A) Calcein Green used to visualize 
cytosolic labile iron levels and (B) RPA used to visualize mitochondrial labile iron 
levels, respectively. Fluorescence quenching is observed after iron binding. (C) BSA-
conjugated Oxyburst Green fluoresces afteroxidation with H2O2 and labile Fe in the 
endosome. 
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a large amount of iron in the endosomes of DMT1 deficient MEL cells compared to control 
(Figure 3.3 A and B). Interestingly this corresponded with reduced cytosolic iron, indicating 
that the iron the MEL cells were taking up via the phagocytosis of transferrin bound iron was not 
making it out of the late endosome (Figure 3.3 A and C). As expected mitochondrial iron was 
also very low in the DMT1 deficient MEL cells (Figure 3.3 A and D). Hinokitiol treatment 
decreased oxyburst green fluorescence 2.1-fold, indicating that the endosome had around the 
same amount of iron in it as control DMT1 replete cells; concomitantly calcein green and RPA 
fluorescence was quenched indicating that the iron that was in the endosome was being released 
into the cytosol and eventually making its way into the mitochondria (Figure 3.3 A-D). These 
data support hinokitiol-mediated release of built-up pools of endosomal iron into the cytosol and 





























































































































































D C B 
Figure 3.3 Hinokitiol releases iron gradients in shDMT1 MEL cells. (A) 
Representative 
fluorescence images of differentiated shControl and DMT1-deficient MEL cells in the 
absence or presence of hinokitiol (1 µM), using OxyBURST Green, calcein green, and 
RPA to detect relative endosomal, cytosolic, and mitochondrial iron levels, 
respectively. A buildup of labile iron was observed in endosomes of DMT1-deficient 
cells, which was released after hinokitiol treatment. (B) ImageJ quantification of 
endosomal oxyburst green (N ≥ 40), (C) cytosolic calcein green (N=23-67) and (D) 
mitochondrial RPA (N=23-67) fluorescence.  
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 We next used calcein green and 55Fe to determine if FPN1 deficiency in J774 
macrophagess causes a similar buildup of iron, in this case inside of the cell, because ferroportin 
is unable to efflux it. When J774 cells were incubated with hepcidin, followed by incubation 
with FeSO4 the hepcidin treated, and therefore FPN1 deficient cells, accumulated more labile 
iron in their cytosol over a one hour time frame than their wild type counterparts (Figure 3.4 A 
and B). Additionally when a similar assay was run with 55Fe, a buildup of total iron was 
observed in the FPN1 deficient cells (Figure 3.4 C). 
 
  
3.3 ARTIFICIAL MANIPULATION OF IRON GRADIENTS REVERSES 
HINOKITIOL’S DIRECTION OF IRON MOBILIZATION  
 In order to determine if the gradients were the main cause of hinokitiol’s directionality, 
we artificially manipulated them in a wild type system. We loaded iron into J774 macrophages, 
rinsed the cells to remove extracellular iron, and stained with calcein green (Figure 3.5 A Left). 
Figure 3.4 FPN1 deficient J774 Macrophages have more intracellular iron than 
their wild type counterparts.  (A and B) A buildup of intracellular labile iron was 
observed in FPN1-deficient J774 macrophages treated with 200 µM FeSO4 by 
quenching of calcein green fluorescence (n = 3). (D) Iron(III) uptake into J774 
macrophages treated with 50 µM FeCl3 similarly revealed a buildup of total 
intracellular iron in FPN1-deficient cells after 4 hours, as observed using 
55
Fe as a 
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Hinokitiol addition (t = 5 min) rapidly increased calcein green fluorescence, indicating iron 
efflux from the cells, whereas vehicle and C2deOHino had no effect (Figure 3.5 A-C). We then 
reversed the gradient in the same cells via external addition of a large bolus of FeCl3 (t = 12 min) 
(Figure 3.5 Right). In DMSO and C2deOHino treated cells there was no significant  effect 
(Figure 3.5 A-C), whereas quenching of calcein green fluorescence was observed with hinokitiol 
treatment (Figure 3.5 A-C). These results are consistent with an initial hinokitiol-mediated 
release of iron from J774 macrophages when intracellular iron levels are high, followed by 
hinokitiol-mediated uptake of iron into these macrophages when this transmembrane gradient is 
reversed by addition of extracellular iron (Figure 3.5 A).  These studies support the hypothesis 
that hinokitiol is merely releasing iron from gradients formed when a protein iron transporter is 
not functioning properly. Collectively they allow us insight into how a simple small molecule 
like hinokitiol, which unlike a protein has no direction bias built in, is able to site- and direction- 
selectively restore iron movement within an iron transporter deficient system to restore normal 
physiology. It also explains why little to no effect is seen when wild type systems are treated 
with hinokitiol (data not shown, refer to A. S. Grillo, A. M. SantaMaria et al.  Science. 20176). 
This implies that there may be a generalizable approach to treating disorders caused by missing 
ion channels by simply by leveraging the gradient of the ion that has built up in the absence of 
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Figure 3.5 Hinokitiol mediated iron transport can be reversed by artificially 
manipulating the iron gradient (A) Schematic of hinokitiol-promoted direction-selective 
iron transport across J774 memebranes using artificial gradients. FeSO4 (200 µM) is first 
loaded into J774 cells, the extracellular fluid is replaced with a low iron media (<500 nM), 
then hinokitiol (100 µM) is added at t = 5 min. Hinokitiol releases iron to the extracellular 
fluid. When the gradient is then reversed by addition of extracellular FeCl3 (100 µM) at t = 12 
min. hinokitiol promotes iron uptake, consistent with direction-selective transport depending 
on the direction of the iron gradient. (B)	Fluorescence imaging of cytosolic iron with calcein 
green, using artificially created iron gradients in opposite directions in J774 macrophages. (C)	
Representative ImageJ quantification of calcein green fluorescence in iron-loaded J774 cells 
with addition of DMSO, hinokitiol, or C2deOHino at t = 5 min and FeCl3 at t = 12 min. 
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3.4 METHODS  
Materials 
 MEL cells were grown in suspension in T25 flasks until ~1x106 cells/mL and re-seeding 
into a new T25 flask at 1x105 cells/mL in MEL Complete media with or without G418. Every 
month of culturing, new backstocks of MEL cells were used. 
 J774 cells (passage 20-80) were grown in T25 flasks to ≥90% confluency before scraping 
and re-seeding at 5:1 dilution in J774 Complete media. Media was changed every 1-2 days. 
 
Live cell fluorescence imaging of MEL cells  
 To visualize cytosolic and mitochondrial iron, confocal imaging of calcein green and 
RPA fluorescence was performed, respectively. MEL cells were induced for differentiation as 
described above. After 70 hours of incubation, iron (III) citrate (10 µM final concentration) was 
added. The cells were incubated for an additional 2 hours, and then were centrifuged and rinsed 
with PBS. The cells were then re-suspended in PBS containing 1 µM calcein green-AM (Thermo 
Fisher C34852) and 1 µM RPA (Axxora SQX-RPA.1). The cells were then incubated at 37 °C 
for 15 minutes. The cells were centrifuged, rinsed with PBS, and re-suspended in DMEM 
containing 10 µM Fe2Tf. The cells were then imaged within 10 minutes on a LSM710 
microscope. Relative calcein green and RPA fluorescence per cell was determined by ImageJ 
analysis using >100 cells per experiment. 
 To visualize endosomal iron levels, confocal imaging of an oxyburst green-BSA 
conjugate (Thermo Fisher O13291) was performed. MEL cells were induced for differentiation 
as described above. After 70 hours, iron (III) citrate (10 µM final concentration) and an oxyburst 
green-BSA conjugate (200 µg/mL) were added. The cells were incubated for an additional 2 
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hours, and then were centrifuged and rinsed with PBS. The cells were then re-suspended in 
DMEM-HEPES buffer, and H2O2 (50 mM final concentration) was added. The cells were 
incubated at room temperature, and the oxyburst green fluorescence was then determined 10 
minutes after addition of H2O2 on a LSM710 microscope. Relative oxyburst green fluorescence 
per cell was determined by ImageJ analysis using >100 cells per experiment. 
 
55Fe uptake into J774 macrophages (Fig. 4D, E) 
 J774 cells were grown in 12-well plates to ~80% confluency. The cells were then treated 
with vehicle or hepcidin in serum-free DMEM media at pH=7.4 in 10 mM HEPES buffer (1 mL) 
containing 50 µM FeCl3 (100:1 56Fe:55Fe). After four hours of incubation at 37 °C, the cells were 
rinsed with PBS (x2), and lysed with 500 µL RIPA buffer containing protease inhibitors. The 
cell lysate was diluted in scintillation cocktail and intracellular 55Fe was determined by liquid 
scintillation counting and normalized to the total protein in each well. 
 Hinokitiol-promoted iron uptake as a function of extracellular iron was performed similar 
to described above in wild type J774 macrophages using 1 µM hinokitiol (from 1000X stock in 
DMSO) and the indicated final concentration of FeCl3 (20:1 56Fe:55Fe). At the indicated time, 
cells were rin sed with PBS (x2), and lysed with 200 mM NaOH. The cell lysate was diluted in 
scintillation cocktail and intracellular 55Fe was determined by liquid scintillation counting and 
normalized to the total protein in each well. 
 
Temporal imaging of cytosolic iron levels in J774 macrophages  
 To assess for the capacity for hinokitiol to reversibly and autonomously transport iron 
across the plasma membrane through the creation of artificial iron gradients, J774 macrophages 
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were grown in Ibidi dishes (Ibidi NC0723624) to ~80% confluency before incubation with J774 
Complete media containing 5 mM ascorbic acid and 200 µM FeSO4. The cells were incubated 
for 1.5 hours, media was aspirated, and the cells were rinsed with PBS. The cells were then 
incubated with calcein green-AM (1 µM) in DMEM for 20 minutes at 37 °C. The media was 
aspirated and cells were rinsed (x2) with PBS before DMEM (pH=7.4 in 10 mM HEPES) and 1 
mM probenecid (Sigma P8761) was added. Calcein green fluorescence was then imaged on a 
LSM880 microscope at 37 °C with 5% CO2 at the indicated time points for 30 minutes. 
Hinokitiol (100 µM final concentration), C2deOHino (100 µM final concentration), or DMSO 
(all from 1000X stocks in 50 µL DMEM) were added at 5 minutes, and a solution of FeCl3 (100 
µM final concentration, in 50 µL DMEM) was added at 12 minutes. Fluorescence in each image 
at each time point was analyzed by ImageJ analysis then normalized to the fluorescence at t = 0 
for each image using >100 cells per experiment. 
 Temporal live cell imaging of iron uptake in wild type and FPN1-deficient J774 cells was 
performed after staining of cells with calcein green as described above. The cells were then 
rinsed with PBS (x2), and incubated in J774 Complete media containing 200 µM FeSO4, 5 mM 
ascorbic acid, and 5 mM probenecid in the presence or absence of hepcidin. Calcein green 
fluorescence was obtained at the indicated time points, and fluorescence in each image at each 
time point was quantified by ImageJ analysis then normalized to the fluorescence at t = 0 for 
each image using >100 cells per experiment. 
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HINOKITIOL INTERFACES WITH THE ENDOGENOUS IRON REGULATORY 
SYSTEM IN ORDER TO RESTORE PHYSIOLOGY 
 
 
4.1 INTRODUCTION  
 With the collective phenomenological and mechanistic data from chapters 1 and 2, 
hinokitiol was beginning to look like a very promising candidate for development as a molecular 
prosthetic to treat human diseases of iron homeostasis. That being said, we wanted to get a better 
understanding of how the natural, endogenous system was interacting with hinokitiol itself, as 
well as the iron that it was mobilizing into, within or out of cells and tissues. We had already 
observed that hinokitiol was not causing an upregulation of the proteins we had knocked down in 
our functional complementation assays (Figures 2.7, 2.12, 2.14); however we wanted to probe 
what else was happening in the cells and tissues when they were treated with hinokitiol. 
Therefore we next asked whether hinokitiol was autonomously carrying iron through the entire 
cell (Figure 4.1 A), or if it was handing the iron off in the cytosol and therefore allowing the 
natural system to take over (Figure 4.1 B). Importantly, if hinokitiol hands the iron off in the 
cytoplasm the endogenous system would be able to interact with the iron brought in by 
hinokitiol. We thus hypothesized that this would allow the cell’s endogenous iron regulatory 
system to adapt to the hinokitiol mediated iron influx, making the down stream affects of 
hinokitiol mediated iron movement a regulated phenomena. This is especially important in gut 
enterocytes, which are crucial in maintaining iron homeostasis. If hinokitiol is able to completely 
bypass the endogenous checks and balances the cell has in place to maintain iron homeostasis, 
the risk of systemic iron overload with hinokitiol treatment would be far greater. We therefore 













 Portions of the work presented in this chapter were preformed with aid from my 
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4.2 ENDOGENOUS PROTEIN ION TRANSPORTERS HELP DRIVE HINOKITIOL-
MEDIATED GROWTH RESCUE IN YEAST 
 We thus asked whether endogenous networks of other ion-transport proteins and 
regulators1 in iron transporter-deficient cells were collaborating with the small molecule, 
Figure 4.1 Does hinokitiol move iron through cells (A) Autonomously or 




hinokitiol, to help promote restoration of site- and direction-selective iron transport while still 
maintaining iron homeostasis. In yeast, the intracellular movement and storage of iron is 
dependent on a proton gradient known as the proton motive force, which is generated by the 
ATP-dependent active ion-transport proteins Pma1 and V-ATPase in the plasma and vacuolar 
membranes, respectively2,3. To test if hinokitiol mediated iron transport depended on the proton 
motive force created by Pma1 and V-ATPase we perfromed a chemical inhibition study where 
we chemically blocked the function of Pma1 and V-ATPase as well as an off target cell process, 
cell wall biosynthesis. We utilized ebselen to block Pma1 activity, bafilomycin to block V-
ATPase activity, and Casponfungin to block cell wall biosynthesis. We treated both the wild type 
and the fet3Δftr1Δ yeast with hinokitiol to rule out any combinatorial effects of treatment with 
two small molecules at the same time. As expected, we observed that hinokitiol-rescued 
fet3Δftr1Δ and wild type yeast are equisensative to caspofungin with an EC50 of 7.9 µM and 7.1 
µM respectively.  In contrast hinokitiol-rescued fet3Δftr1Δ are exceptionally sensitive to 
chemical inhibition of Pma1 compared to wild type yeast with an EC50 of 0.4 µM and 2.1 µM 
respectively.  Hinokitiol-rescued fet3Δftr1Δ are also exceptionally sensitive to chemical 
inhibition of V-ATPase compared to wild type with an EC50 of 24.4 µM and 29.2 µM 
respectively. These reulsts are  consistent with the dependence of hinokitiol-mediated iron 









































































































































Figure 4.2 Hinokitiol collaborates with the endogenous proton pumps in yeast in 
order to restore physiology. (A) Schematic of  fet3Δftr1Δ with ebselen and 
bafilomycin chemically inhibiting the active proton transporters Pma1 and V-ATPase. 
(B) As expected, wild type and fet3Δftr1Δ yeast grown in the presence of hinokitiol (10 
µM) are equisensitive to an inhibitor of cell wall biosynthesis, caspofungin, which is off-
pathway of iron uptake. N = 3.  Inhibition of the proton-motive force generating pumps, 
(C ) Pma1 with ebselen and (D) V-ATPase with bafilomycin, lead to increased 
sensitivity of hinokitiol-rescued fet3Δftr1Δ yeast relative to hinokitiol-treated wild type 
yeast. This suggests these proteins play a role in hinokitiol-mediated restoration of yeast 
cell growth. N = 3. 
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4.3 HINOKITIOL INTERFACES WITH ENDOGENOUS PROTEINS IN MAMMALIAN 
CELLS TO RESTORE PHYSIOLOGY  
 In intestinal epithelia, iron-transport proteins are transcriptionally and translationally 
regulated to maintain pysiological systemic iron levels while avoiding overload1,4,5. Specifically, 
levels of the apical H+/Fe2+ symporter Divalent Metal Transporter 1 (DMT1), the iron 
sequestration protein ferritin (heavy, FTH1 and light, FTL1 chains), the basolateral efflux protein 
ferroprotin (FPN1), and the iron uptake mediator transferrin receptor 1 (TfR1) are translationally 
regulated through short hairpin iron response elements (IREs) located at the 5’- and 3’-
untranslated regions of the corresponding mRNA transcripts (Figure 4.3)1,5–7. Iron-sensing iron 
response proteins (IRP1 and IRP2) bind to these IREs to block translation (5’-IRE, Fth1, Ftl1, 
Fpn1) or stabilize mRNA (3’-IRE, Dmt1, TfR1) under iron starvation (Figure 4.3 A). Upon iron 
stimulation and binding, the IRPs dissociate from the mRNAs, reversing their described effects. 
Transcriptional regulation is achieved through the transcriptional activator, hypoxia-inducible 
factor 2-alpha (Hif2α), which is degraded after O2 and iron-mediated proline hydroxylation 
(Figure 4.3 B)1. Interestingly, Hif2α activates transcription of an isoform of Fpn1 in order to 




 Consistent with the iron homeostatic mechanisms mentioned above, an anemic state8 is 
initially observed in DMT1-deficient Caco-2 monolayers, with decreased levels of ferritin and 
increased levels of FPN1, TfR1, and IRP2 (Figure 4.4 A-E), and as expected no significant 














































 Figure 4.3 Simplified schematics for translational and transcriptional regulation of iron 
related proteins. (A) Translational regulation in duodenal enterocytes is mediated through 
iron response elements (IREs) located on the 5’ or 3’ ends of mRNA of several iron-related 
proteins. In the absence of iron, iron response proteins (IRP1 and IRP2) bind to the 5’- or 3’-
IRE to block translation or stabilize mRNA, respectively. Upon iron binding, IRP1/2 
dissociate from IRE (and IRP2 is degraded) and translation occurs (5’-IRE) or mRNA 
degrades (3’-IRE) to allow for ironsensitive regulation of proteins involved in iron uptake and 
transport. (B) Transcriptional regulation of FPN1 via Hif2α occurs to evade translational 
repression of FPN1. Hif2α activates Fpn1 transcription under iron-deplete conditions, 




favorable cellular environment for small molecule-mediated iron transport. This “priming” of the 
system toward unidirectional iron transport is likely critical for hinokitiol mediated iron 
mobilization into, within and out of cells.  
 
 Providing support for functional collaboration with these endogenous proteins, hinokitiol-
mediated iron uptake and transport across DMT1-deficient Caco-2 monolayers is unidirectional 
(Figure 4.5 A and B). When both hinokiitol and iron are added to the basolateral side, hinokitiol 






































































































































































































































B ED C 
F G IH
Figure 4.4 DMT1 deficient Caco-2 monolayers are in an anemic state. (A) Representative 
Western blot images of proteins involved in iron absorption and regulation indicate an anemic 
state in shDMT1 Caco-2 monolayers to promote maximal iron absorption. (B-I) Western blot 
or ELISA quantification of protein levels of iron-related proteins in shDMT1 Caco-2 
monolayers indicate other proteins respond via transcriptional and translational feedback 
mechanisms to changes in cellular iron status. Importantly, (B) decreased ferritin and (C) 
increased FPN1 levels were observed, presumably creating an environment favorable for 
small molecule-mediated iron transport. N = 3-16.    
	
	100	
iron the cell has established. Therefore iron does not accumulate and show up as increased 
uptake in the assay. It is possible however, that hinokitiol is indeed moving iron across the 
basolateral membrane, however because of the proximity to high levels of FPN1, which is being 
upregulated in response to the anemic state, the hinokitiol mediated iron influx is merely 
effluxed back into the basolateral fluid. In either case, this leads to no inrease in uptake or 
transport to the apical side.  
 Apical treatment with this low dose of hinokitiol (500 nM) allows for 55Fe incorporation 
into ferritin (Figure 4.5 C), this increase incorporation of 55Fe into ferritin in hinokitiol treated 
shDMT1 cells is strong evidence that hinokitiol is either deilvering the iron directly to ferritin, 
releasing it into the cytosol, or handing it off to the high affinity iron chaperone Poly (rC)-
binding protein 1 (PCBP1). PCBP1 is known to shuttle excess iron in the cytosol to ferritin 
where it is stored in order to abate the toxic effects seen with large amounts of excess, labile 
iron1,9–11.  Finally, quercetin-mediated knockdown of FPN112 antagonizes hinokitiol-mediated 
transmembrane transport without affecting apical uptake, indicating that at the concentration of 
hinokitiol that is  efficatious in the DMT1 deficient Caco-2 cells, the basolateral efflux is 
ferroportin mediated (Figure 4.5 D-G). This is another strong piece of evidence that hinokitiol is 
releasing iron into the cytosol and allowing for the endogenous iron transporting system and 
regulatory network to take over. Interestingly, if hinokitiol is added to the basolateral side and 
55Fe is added to the apical side iron transport is observed, although it is slightly delayed 
compared to apically added hinokitiol. This suggests that hinokitiol is going into the Caco-2 
monolayer from the basolateral side, going through the cell and the apical membrane and then 
grabbing iron from the apical side and allowing it to get into the cell where it is then transported 





  Collectively these studies demonstrate that hinokitiol is interacting with the endogenous 
iron transport and regulatory systems and is therefore not supassing all of the checks and 
balances estabilished by the cell. This is encouraging because it has great implications for the use 
Figure 4.5 The endogenous network of iron regulators is involved in hinoktiol mediated 
Caco-2 iron transport. (A and B) Unidirectional hinokitiol-mediated (A) transport and (B) 
uptake in shDMT1 Caco-2 monolayers observed with apical or basolateral addition of 
hinokitiol (500 nM) and 55Fe radiotracer (n = 3). (C) Determination of 
55
Fe levels in 
immunoprecipitated ferritin in Caco-2 monolayers (n = 3). (D) Quercetin (250 µM) treatment 
for 18 hours decreased FPN1 levels in shDMT1 Caco-2 monolayers by western blotting 
analysis. N = 16 (E) Knockdown of FPN1 in shDMT1 Caco-2 monolayers with quercetin 
abrogates hinokitiol-mediated transport (n = 3). (F) Quercetin-mediated knockdown of FPN1 
in Caco-2 monolayers did not affect iron uptake into these cells in the presence and absence 






































































































































































































of hinokitiol as a theraputic as well as the potential for other diseases cause by missing ion 
transporters to be treated in a similar, regulated way. Because hinokitiol is effective at such low 
doses, we wanted to explore what would happen at higher doses in the same systems, Chapter 5 
goes into those effects in detail.  
  
4.4 METHODS            
Materials 
 Wild type (DEY1457) and isogenic fet3Δftr1Δ S. cerevisiae were obtained from D. 
Kosman13. Wild type (YPH499) and isogenic fet3Δarn1-4Δ S. cerevisiae were obtained from C. 
Philpott14. Yeast were maintained on standard YPD media containing 10 g/L yeast extract, 20 
g/L peptone, and 20 g/L dextrose without (liquid media) or with (solid media) 20 g/L agar. 
Unless otherwise indicated, growth-restoration assays in yeast used a low iron SD media 
consisting of 1.91 g/L iron-free YNB-FeCl3 (ForMedium CYN 1201), 0.79 g/L Complete 
Supplement Mixture (Sunrise Science Products 1001-010), 5 g/L ammonium sulfate (Sigma 
A4418), 20 g/L dextrose, 10 µM FeCl3 (Sigma 451649), and 10 µM hinokitiol (β-Thujaplicin, 
Sigma 469521) in 50 mM MES/Tris buffer at pH=7.0 without (liquid media) or with (solid 
media) 20 g/L agar. Dextrose, hinokitiol, and FeCl3 were added after autoclave sterilization from 
a filter-sterilized 40% w/v dextrose solution in water, from a freshly prepared sterile 10 mM 
hinokitiol stock in DMSO, and from a freshly prepared 10 mM FeCl3 stock in sterile water, 
respectively. Non-fermentable growth restoration used the same synthetic medium except for the 
use of 30 g/L glycerol instead of dextrose.  
 Human Caco-2 cells (HTB-37) and mouse macrophages (J774A.1) were obtained from 
ATCC and cultured with DMEM (Gibco 10313-021) containing 10% HI FBS (Gibco 16000-
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036), 4 mM glutamine (Lonza BE17-605E), 100 µg/mL PEN-STREP (Lonza DE17-602E), and 
1% MEM NEAA (Fisher 11140-050). Transfected Caco-2 cell lines were maintained on this 
media containing 800 mg/L G418 (Santa Cruz sc-29065B). Friend mouse erythroleukemia cells 
(MEL, DS19 subclone) were obtained from Arthur Skoultchi (Albert Einstein College of 
Medicine, Bronx, NY) and cultured with DMEM containing 10% HI FBS, 2 mM glutamine, 100 
µg/mL PEN-STREP, and 1% MEM NEAA. Transfected shControl and shDMT1 MEL cell lines 
were maintained on this media containing 1 g/L G418. 
 Caco-2 cells (passage 18-50) were grown in T75 flasks to ≥90% confluency before 
trypsinization with 0.25% trypsin-EDTA (Fisher 25200-056) and passaging at 10:1 dilution in 
Caco-2 media without (wild type) or with G418 (transfected). Monolayers were grown by 
seeding Caco-2 cells (passage 20-50) onto 0.4 µm PET cell culture inserts (Fisher 08-771) in 6-
well companion plates (Fisher 08-771-24) at 2x105 cells/well and allowed to fully differentiate 
for 21-28 days before experiments were performed with changing of media every 3-4 days.  
 MEL cells were grown in suspension in T25 flasks until ~1x106 cells/mL and re-seeding 
into a new T25 flask at 1x105 cells/mL in MEL Complete media with or without G418. Every 
month of culturing, new backstocks of MEL cells were used. 
 J774 cells (passage 20-80) were grown in T25 flasks to ≥90% confluency before scraping 
and re-seeding at 5:1 dilution in J774 Complete media. Media was changed every 1-2 days. 
 
Statistics 
 All data depicts the means or weighted mean ± SEM with a minimum of 3 biological 
replicates unless otherwise noted. Statistical analysis represents P values obtained from student t-
test or one- or two-way analysis of variance (ANOVA) with post-hoc TUKEY test where 
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appropriate. NS, not significant; * P < 0.05; ** P ≤ 0.01; *** P ≤ 0.001; **** P ≤ 0.0001 unless 
otherwise noted. 
 
Growth rescue of fet3Δftr1Δ yeast with small molecules in liquid media  
 Growth rescue in yeast was performed similar to previously reported15 using 10 µM 
hinokitiol in low iron SD liquid media containing 10 µM FeCl3 in a 96-well plate unless 
otherwise noted. Wild type and fet3Δftr1Δ controls treated with vehicle (DMSO) were 
performed under identical conditions using the same low iron SD media containing 10 µM FeCl3 
in the absence of hinokitiol. Yeast were grown overnight in YPD media and diluted at an OD600 
of 0.1 in SD media, diluted 10-fold, and incubated at 30 °C with continuous shaking (200 rpm). 
The OD600 was obtained 24-48 hours after inoculation unless otherwise noted.  
 Small molecule dose-response with hinokitiol and C2-deoxy hinokitiol (C2deOHino, see 
synthesis below) was determined by addition of the small molecule (40X stock solution in 
DMSO) to give the indicated final concentrations.  
 
Chemical inhibition of yeast cell growth with inhibitors of Pma1, V-ATPase  
 Chemical inhibition of hinokitiol-treated wild type and hinokitiol-rescued fet3Δftr1Δ 
yeast cell growth was performed as previously reported15 in low iron SD media containing 10 
µM FeCl3 and 10 µM hinokitiol. Increasing dosages of caspofungin (Sigma SML0425), ebselen 
(Sigma 70530), or bafilomycin B1 (Santa Cruz sc-202072) (40X stocks in DMSO) were added to 
a yeast suspension (10-fold dilution from OD600 = 0.1) to give the indicated final dose. EC50 




Western blotting conditions  
 Caco-2 monolayers, differentiated MEL cells, or J774 cells underwent treatment as 
described in rescue experiments before lysis with RIPA buffer (Thermo 89901) containing 
protease inhibitors (Thermo 88266). Protein concentrations were determined by a BCA kit 
(Thermo 23225) and diluted to 2 mg/mL in the same RIPA buffer. Relative protein levels were 
then determined through western blotting of 10 or 20 µg of protein lysate blocking for 2 hours at 
room temperature with 5% BSA and using primary antibodies consisting of either human anti-
DMT1 (1:3,000 dilution, Santa Cruz sc-30120), mouse anti-DMT1 (1:1,000 dilution, Santa Cruz 
sc-166884), human anti-FTL1 (1:1,000 dilution, Santa Cruz sc-74513), human anti-FPN1 HRP 
conjugate (1:10,000 dilution, Novus Biologicals NBP1-21502H), mouse anti-globin α HRP 
conjugate (not heated at 100 °C, 1:10,000 dilution, Lifespan Biosciences LS-C212172), human 
anti-TfR1 HRP conjugate (1:10,000 dilution, Abcam ab10250), human anti-IRP1 (1:1,000 
dilution, Santa Cruz sc-14216), human anti-IRP2 (1:1,000 dilution, Santa Cruz sc-33682), human 
anti-Hif1α HRP conjugate (1:1,000 dilution, Novus Biologicals NB100-105H), human anti-
Hif2α HRP conjugate (1:1,000 dilution, Novus Biologicals NB100-122H), human anti-PCBP1 
(1:1,000 dilution, Santa Cruz sc-393076), or human anti-actin HRP conjugate (1:10,000 dilution, 
Cell Signaling 5125S) in 5% BSA overnight at 5 °C before rinsing thoroughly with TBST and 
incubation (if non-HRP conjugated) with secondary antibody consisting of either goat anti-rabbit 
IgG HRP conjugate (1:5,000 dilution – DMT1, Cell Signaling 7074, in 5% milk), goat anti-
mouse IgG1 HRP conjugate (1:1,000 dilution – PCBP1, 1:5,000 dilution – IRP2, 1:3,000 dilution 
– DMT1, Santa Cruz sc-2060, in 5% BSA), donkey anti-goat IgG HRP conjugate (1:1,000 
dilution – IRP1, Santa Cruz sc-2020, in 5% BSA), or goat anti-mouse IgG2a HRP conjugate 
(1:10,000 dilution – FTL1, Santa Cruz sc-2061, in 5% BSA) at room temperature for two hours. 
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Blots were thoroughly rinsed with TBST and imaged after addition of Femto Chemluminescence 
solution according to manufacturer instructions (Thermo Fisher 34095).  
 
Determination of ferritin levels by ELISA  
 Absolute ferritin protein levels in shControl and shDMT1 Caco-2 monolayer lysates were 
determined using a commercial sandwich ELISA kit (Abcam ab108837) according to 
manufacturer instructions. 
 For results found in fig. S14E, protein lysate was isolated after treatment with 500 nM 
FeCl3 as described below.  
 
55Fe uptake and transport in differentiated Caco-2 monolayers  
 Media from differentiated Caco-2 monolayers (P25-50, 21-28 days post seeding) grown 
on PET inserts in 6-well plates was aspirated, and monolayers were rinsed with PBS. 2 mL of 
basolateral fluid (serum-free DMEM at pH = 7.4 in 10 mM HEPES buffer) was added to the 
basolateral side, and 1 mL of apical fluid (serum-free DMEM at pH = 5.5 in 10 mM MES buffer) 
containing 200 nM 55FeCl3 or the indicated concentration of FeCl3 and either DMSO vehicle, 
hinokitiol, C2deOHino, deferiprone, PIH, SIH, or deferoxamine mesylate (Sigma D9533) (500 
nM Hino/C2deOHino for DMT1-deficiency, 1 µM Hino/C2deOHino for FPN1-deficiency, or 
indicated concentration of small molecule from a 1000X stock in DMSO) was added to the 
apical side via addition on the wall of the membrane insert without disrupting the cell monolayer. 
The monolayers were then incubated for four hours at 37 °C unless otherwise noted. A 100 µL 
aliquot of the basolateral fluid was removed, diluted in scintillation cocktail, and radioactivity 
was determined on a liquid scintillation counter to quantify relative amounts of 55Fe transport. To 
determine intracellular 55Fe, the basolateral and apical media was removed, and the monolayer 
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was rinsed with PBS (x2). The cells were then lysed with 500 µL of 200 mM NaOH with nutator 
mixing overnight, and radioactivity was determined on a liquid scintillation counter after diluting 
the cell lysate in scintillation cocktail. All values were normalized to shControl monolayers 
unless otherwise noted. Absolute iron levels were determined through calibration of 55Fe 
radioactivity levels with known standards and average mg of protein per membrane was 
determined by protein lysis with RIPA buffer containing protease inhibitors and quantified 
through a BCA kit according to manufacturer instructions.  
 Determination of unidirectional uptake and transport was determined as described above 
except for basolateral addition of 55FeCl3 (200 nM) and basolateral addition of DMSO or 
hinokitiol (500 nM). An aliquot of the apical fluid was then taken to determine the basolateral to 
apical transport. Intracellular 55Fe was determined as described above. 
 Determination of 55Fe transport after FPN1 knockdown was determined as described 
above using 200 nM 55FeCl3 after incubation of quercetin to knockdown FPN112 as described 
below. 
  
55Fe immunoprecipitation of ferritin in Caco-2 monolayers  
 Immunoprecipitation of ferritin was performed using human anti-FTL1 (Santa Cruz sc-
74513) and Protein G PLUS-Agarose beads (Santa Cruz sc-2002). Cell lysate was obtained from 
shControl and shDMT1 Caco-2 monolayers after apical treatment with 200 nM FeCl3 for four 
hours as described above. Cell lysate was incubated with primary antibody (1:100 dilution) at 
room temperature for 1 hour, then with the secondary antibody (1:10 dilution) at room 
temperature for 1 hour with constant mixing. Repeated centrifugations and PBS rinses were 




Knockdown of FPN1 in Caco-2 cells  
 To knockdown FPN1 levels in wild type Caco-2 cells, the differentiated epithelial 
monolayers were incubated with 150 µM quercetin (Sigma 337951) for 18 hours in Caco-2 
Complete media containing G418 similar to previously described12. To knockdown FPN1 levels 
in shControl and shDMT1 Caco-2 monolayers, incubation was performed as above except with 
250 µM quercetin. After completion of the incubation, the apical and basolateral fluid was 
aspirated and rinsed with PBS before 55Fe transport and uptake were determined as described 
above. 
 
Live cell fluorescence imaging of MEL cells  
 To visualize cytosolic and mitochondrial iron, confocal imaging of calcein green and 
RPA fluorescence was performed, respectively. MEL cells were induced for differentiation as 
described above. After 70 hours of incubation, iron (III) citrate (10 µM final concentration) was 
added. The cells were incubated for an additional 2 hours, and then were centrifuged and rinsed 
with PBS. The cells were then re-suspended in PBS containing 1 µM calcein green-AM (Thermo 
Fisher C34852) and 1 µM RPA (Axxora SQX-RPA.1). The cells were then incubated at 37 °C 
for 15 minutes. The cells were centrifuged, rinsed with PBS, and re-suspended in DMEM 
containing 10 µM Fe2Tf. The cells were then imaged within 10 minutes on a LSM710 
microscope. Relative calcein green and RPA fluorescence per cell was determined by ImageJ 
analysis using >100 cells per experiment. 
 To visualize endosomal iron levels, confocal imaging of an oxyburst green-BSA 
conjugate (Thermo Fisher O13291) was performed. MEL cells were induced for differentiation 
as described above. After 70 hours, iron (III) citrate (10 µM final concentration) and an oxyburst 
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green-BSA conjugate (200 µg/mL) were added. The cells were incubated for an additional 2 
hours, and then were centrifuged and rinsed with PBS. The cells were then re-suspended in 
DMEM-HEPES buffer, and H2O2 (50 mM final concentration) was added. The cells were 
incubated at room temperature, and the oxyburst green fluorescence was then determined 10 
minutes after addition of H2O2 on a LSM710 microscope. Relative oxyburst green fluorescence 
per cell was determined by ImageJ analysis using >100 cells per experiment. 
 
Temporal imaging of cytosolic iron levels in J774 macrophages 
 To assess for the capacity for hinokitiol to reversibly and autonomously transport iron 
across the plasma membrane through the creation of artificial iron gradients, J774 macrophages 
were grown in Ibidi dishes (Ibidi NC0723624) to ~80% confluency before incubation with J774 
Complete media containing 5 mM ascorbic acid and 200 µM FeSO4. The cells were incubated 
for 1.5 hours, media was aspirated, and the cells were rinsed with PBS. The cells were then 
incubated with calcein green-AM (1 µM) in DMEM for 20 minutes at 37 °C. The media was 
aspirated and cells were rinsed (x2) with PBS before DMEM (pH=7.4 in 10 mM HEPES) and 1 
mM probenecid (Sigma P8761) was added. Calcein green fluorescence was then imaged on a 
LSM880 microscope at 37 °C with 5% CO2 at the indicated time points for 30 minutes. 
Hinokitiol (100 µM final concentration), C2deOHino (100 µM final concentration), or DMSO 
(all from 1000X stocks in 50 µL DMEM) were added at 5 minutes, and a solution of FeCl3 (100 
µM final concentration, in 50 µL DMEM) was added at 12 minutes. Fluorescence in each image 
at each time point was analyzed by ImageJ analysis then normalized to the fluorescence at t = 0 
for each image using >100 cells per experiment. 
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 Temporal live cell imaging of iron uptake in wild type and FPN1-deficient J774 cells was 
performed after staining of cells with calcein green as described above. The cells were then 
rinsed with PBS (x2), and incubated in J774 Complete media containing 200 µM FeSO4, 5 mM 
ascorbic acid, and 5 mM probenecid in the presence or absence of hepcidin. Calcein green 
fluorescence was obtained at the indicated time points, and fluorescence in each image at each 
time point was quantified by ImageJ analysis then normalized to the fluorescence at t = 0 for 
each image using >100 cells per experiment. 
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AT HIGH CONENTRATIONS HINOKITIOL SEQUESTRS 
 IRON INTRACELLULARLY  
 
 
5.1 INTRODUCTION  
 In Chapter 4 I described the anemic markers of protein expression that we observed in the 
iron transporter deficient cells and the ability of hinokitiol to interface with the endogenous 
system of ion transporters and iron regulatory proteins and channels. Because hinokitiol is 
interfacing with the endogenous system we thus explored what would happen in protein 
transporter deficient systems with treatment of a range of concentrations of hinokitiol. We 
hypothesized that at intermediary concentrations of hinokitiol the influx of iron would cause the 
IRE controlled protein expression to revert from an anemic expression profile to that of a non-
anemic or wild type protein expression profile. At high concentrations of hinokitiol we expected 
the treated cell’s expression profile to look like a cell that is experiencing iron overload, 
specifically with high levels of ferritin, and low levels of TfR1, IRP2, FPN1, Hif1α, and Hif2α. 
With the change in expression of these proteins we also expected to see a rise and fall of the iron 
transport indicating that the natural system is regulating hinokitiol mediated iron transport. The 
studies in this chapter aim to understand how the natural system reacts to hinokitiol at high 
concentrations as well as causes for the potential loss of efficacy and/or toxicity.  
 Portions of the work presented in this chapter were preformed with aid from my 
colleagues Dr. Anthony Grillo and Dr. Alexander Cioffi, and our undergrads Chris Nardone, and 
James Fan. Portions of this chapter have been adapted from Grillo, A. S.; SantaMaria A. M.; 
Kafina M. D.; Cioffi A.G.; Huston N. C.; Han M.; Seo Y. A.; Yien Y.Y.; Nardone C.; Menon A. 
V.; Fan J.; Svoboda D. C.; Anderson J. B.; Hong J.D.; Nicolau B. G.; Subedi K.; Gewirth A. A.; 
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Wessling-Resnick M.; Kim J.; Paw B. H.; Burke M. D. “Restored iron transport by a small 
molecule promotes absorption and hemoglobinization in animals” Science. 2017, 356, 608-616. 
Reprinted with permission from AAAS. 
 
5.2 HINOKITIOL BINDS MANY DIFFERENT DIVALENT METALS   
 Because the alpha hydroxyl ketone is a very common binding motif for many different 
divalent metals, and even trivalent metals, we first asked whether hinokitiol was causing toxicity 
via the mobilization and therefore disregulation of other off target metals with in the system. To 
get a more complete understanding we looked at hinokitiol’s ability to bind and transport other 
divalent metals in vitro.  Using modified partition assays, combined with ICP-MS, we extracted 
hinokitiol iron complexes from aqueous buffer and then quantified the concentration of metal in 
the organic layer.  We found that hinokitiol acted as a broad spectrum metallophore and is 
capable of binding multiple divalent metals (Figure 5.1 A and B and Table 5.1). Specifically 
hinokitiol can bind Iron, Manganese, Cobalt, Nickel, Zinc and Copper (Figure 5.1 A). In order 
to determine hinokitiol’s specificity for each of the divalent metals tested we performed a 
competition assay with stoichiometric amounts of hinokitiol and all of the metals listed above. 
Surprisingly, we found that hinokitiol competitively bound 10-fold more CuII than FeII  (Table 
5.1).  We next looked at how well hinokitiol mobilized these metals out of liposomal systems. 
Once again we found that hinokitiol not only bound copper better than iron but also transported 
CuII  80-fold faster than FeII . When first encountering these numbers they can be quite daunting 
until the low accessibility of copper is considered.  Specifically, the cytosolic labile copper pool 
is ten billion times lower than iron, which is the most abundant divalent metal in the body, by 




   
Figure 5.1. Selectivity of hinokitiol-mediated binding and transport with divalent 
cations. (A) Metal content in aqueous layer before extraction (black bars) and the organic 
layer after extraction with 1:1 Hexanes:Ethyl Acetate (white bars) using 10:1 Hino:Metal 
indicates hinokitiol forms organic soluble complexes with each individual metal. No metal 
was detected in the organic layer in the absence of hinokitiol. N = 3. (B) Stoichiometric 
competition experiments with 1 mM of each divalent metal and 1 mM hinokitiol in a 10 mM 
Mes/Tris buffer in 1:1 MeOH:H2O at pH=7.0. Hinokitiol binds many metals by ICP-MS 
quantification of extracted hinokitiol-bound metal. The metal in the organic layer was 
determined to be in the order of Cu > Fe > Mn ≈ Zn > Co > Ni. ND = Not detected. N = 6. (C) 
Hinokitiol (10 µM) rapidly promotes the efflux of multiple divalent metals from POPC 
liposomes as determined by a PhenGreen assay. In these studies, hinokitiol was unable to 
transport MnII to any observable degree. Quantification of metal release was done by 
comparison of fluorescence quenching to a standard curve for each metal. The reciprocal half-
lives for efflux were determined to be in the order of Cu > Zn > Co > Ni > Fe >> Mn. The 
values for binding and transport, as well as the labile metal levels found inside of cells, can be 









































 60 mM Hino and 1 mM of each metal in 10 mM Mes/Tris in 1:1 MeOH:H2O at pH=7.0
† 1 mM Hino and 1 mM of each metal in 10 mM Mes/Tris in 1:1 MeOH:H2O at pH=7.0
‡ Estimated cytosolic labile metal found inside of cells: Reference 33 and 34
Table 5.1 Selectivity of hinokitiol binding and transport. Hinokitiol binds and 
transports many divalent metals, as determined by ICP-MS analysis of organic-soluble 
hinokitiol:metal complexes after extraction and by determination of the rates of metal 
efflux from liposomes. The selectivity for binding and transport in biological systems 
is likely high for iron due to the high metallomic abundance of labile iron over other 




 We thus hypothesized that the low level of labile copper present would lead to high iron 
selectivity in vivo1–3. This is attributed to robust networks of transporters, chaperones, storage 
proteins, and regulators that bind CuII with exceptional affinities and selectivities thus 
sequestering the copper away from hinokitiol3. For example, the transcriptional activator Mac1, 
which is essential in regulating yeast copper homeostasis, binds copper with a KD of 9.7 x 10-20 
M3. We thus hypothesized that in our systems hinokitiol would only cause a net movement of 
iron and not the other metal ions it is able to bind and transport, due to lack of gradients of the 
other metal ions, low labile pools, as well as other metal ion homeostasis mechanisms that would 
correct any aberrant metal ion movement to maintain homeostasis.   
 In order to test our hypothesis on a living system we turned to our fet3Δftr1Δ yeast model 
system. Upon treatment of fet3Δftr1Δ yeast with hinokitiol, lysis, digestion and ICP-MS 
quantification we found intracellular iron levels to increased relative to vehicle-treated controls, 
whereas levels of manganese, cobalt, nickel, zinc, and copper were unchanged (Figure 5.2). 
Other biologically relevant ions, such as Magnesium, Sodium, and Potassium also remained 
unchanged (data not shown).  



































































Figure 5.2 Hinokitiol only causes a net movement of iron in fet3Δftr1Δ yeast. Hinokitiol-
mediated changes in intracellular metal levels were determined by growing treating 
fet3Δftr1Δ yeast with vehicle or hinokitiol (10 µM) for 2.5 h and the intracellular metal 
content was quantified by ICP-MS. Intracellular iron levels increased in hinokitiol-treated 
fet3Δftr1Δ yeast relative to vehicle-treated controls, whereas levels of manganese, cobalt, 
nickel, zinc, and copper were unchanged N = 3.   
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5.3 HINOKITIOL DOES NOT TAKE IRON AWAY FROM IRON BINDING PROTEINS   
 Another potential cause of toxicity is hinokitiol’s ability to bind iron extremely tightly. 
Hinokitiol binds both ferrous and ferric iron very strongly with a KA = 5.1x1015 for ferrous iron 
and KA = 5.8x1025 for ferric iron, the latter of which is more than an order of magnitude stronger 
than deferiprone (Figure 5.3 A and Table 5.2). There is therefore a real concernt that hinokitiol 
could potentially take iron away from iron binding proteins and even disrupt iron-sulfur clusters, 
which are critical for many protein functions. In competition experiments, in a buffered system 
we found that hinokitiol can remove iron from iron-binding proteins such as transferrin and 
ferritin. However this was only possible when hinokitiol was in >1,000-fold excess relative to 




that magnitude are not possible in a cellular system so we were confident that hinokitiol would 
not take iron away from most iron binding proteins.  In fact, 56Fe bound to hinokitiol readily 
exchanges with 55Fe in solution. We found that the exchange rate between hinokitiol and iron to 
be incredibly rapid, with >20% exchange observed within 10 minutes (Figure 5.3 E). This is 
most likely facilitated by Hinokitiol’s pKa. Hinokitiol has a pKa = 7.33 suggesting both the 


























































































































Figure 5.3 Biophysical studies on the binding of iron and hinokitiol. (A) Hinokitiol 
strongly binds iron (III) relative to deferiprone as determined by the EC50 values obtained 
from an EDTA competition study. N = 3. (B) Transferrin (100 µM) saturated with iron is not 
denatured after extraction with ethyl acetate. (C and D) Hinokitiol removes iron from (C) 
transferrin (1 nM) and (D) ferritin (2.5 ng ferritin/mL) in a dose-dependent fashion using 
55
Fe 
as a radiotracer. N = 3. (E) Stoichiometric ionic 
55
Fe was added to a solution containing a pre-
formed 
56
Fe-hinokitiol complex in 10 mM Mes/Tris buffer at pH=7.0. Equilibrium between 
the 
55
Fe-hinokitiol complex and the 
56
Fe-hinokitiol complex was achieved within one hour. N 
= 3. (F) Increased absorbance of the peak at 387 nm for hinokitiol increases with increasing 
pH.  A clear isobestic point is observed (365 nm), indicating speciation between the 
protonated and deprotonated forms of hinokitiol. pKa was calculated through logistic fitting 
of the plot of Abs387/Abs240 vs. pH on OriginPro (R
2
 = 0.996). 
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Hinokitiol does not bind iron as strongly when the hydroxyl group is protinated,  therefore  it is 
likely that the pKa contributes to its ability to readily exchange with the proteins within the cell. 
Adding to this phenomena is the fact that hinokitiol does not bind ferrous iron as well as ferric. 
We hypothesize that once the iron is released in the cytoplasm the reducing nature of the 
intracellular environment will keep the iron as FeII and therefore the hinokitiol will have less of 
an affinity for it. Thus, the binding of iron by hinokitiol under physiological conditions is 
expected to be highly dynamic, which may be the key to allow for the facile release of iron from 
hinokitiol complexes to iron-binding proteins and its subsequent use in iron-related physiological 
processes. We therefore concluded that at the concentrations at which we are seeing efficaey, 










































E0 (mV vs. N.H.E.)
Literature values indicated in parenthesis
Literature values not run under identical conditions
* Reference 60
† Estimated from known pFe of EDTA (pFe = 22.2): Ref 104
‡ Estimated from known pFe of Citrate (pFe = 14.8): Ref 105
§Reference 106
|| Reference 104












Table 5.2. Physical characteristics of iron chelators. Binding affinities and redox potentials 
of hinokitiol and other chelators was determined through competition assays and cyclic 
voltammetry, respectively. Hinokitiol binds iron (II) and iron (III) stronger than many other 
iron chelators, including deferiprone. The iron:hinokitiol complex is soluble in non-polar 
solvents as determined by its octanol-water partition coefficient. Values represent means. 
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5.4 HINOKITIOL CAUSES INTRACELLULAR IRON SEQUESTRATION AT HIGH 
CONCENTRATIONS 
 Hinokitiol is toxic to yeast at high concentrations; due to hinokitiol’s ability to bind and 
transport iron Occam's razor would suggest that the associated toxicity is somehow connected 
with iron. We thus hypothesized that we could extend the theraputeic window in yeast just by 
adding in iron. Increasing concentrations of iron increased the minimum inhibitory concentration 
(MIC) in both wildtype and fet3Δftr1Δ yeast (Figure 5.4) but other divalent metals failed to have 
the same affect (Data not shown).  
  
 So far all of the data I have presented is evidence in support of the hypothesis that 
hinokitiol is interfacing with the endogenous system and therefore hinokitiol-mediated iron 
mobilization within cells is a regulated phenomena. We thus set out to test the hypothesis that 
with increasing concentrations of hinokitiol, the concomitant increase in cytosolic iron would 
cause the cell’s protein expression profile to imitate an iron overload expression profile with high 
levels of ferritin, and low levels of TfR1, IRP2, FPN1, Hif1α, and Hif2α. We first probed what 
iron transport in DMT1 deficient caco-2 cells looks like at high hinokitiol and iron 
concentrations.  









































 We first treated Caco-2 monolayers with increasing concentrations of hinokitiol. The 
increase in hinokitiol concentration caused and increase in the amount of iron taken into the cell, 
however the transport leveled off at 5 µM  and and actually began to decrease at 25 µM. (Figure 
5.5).  To us this indicated that somehow hinokitiol mediated transport, even at concentrations 
orders of magnitutde over those that are efficatious, is a regulated phenomena.  
 
 With this interesting phenominological data in hand, we next asked how the endogenous 
system responds to the hinokitiol-mediated changes in cellular iron status in the presence of a 
persistent iron gradient. Consistent with IRP-mediated translational regulation, decreased IRP2, 
increased ferritin subunits (5’-IREs), and decreased TfR1 (3’-IRE) protein levels were observed 
as a function of hinokitiol concentrations up to 5 µM in the presence of a persistent iron gradient 
(Figure 5.6 A-F). The transcription factors Hif1α and Hif2α similarly decreased along with 
decreased Fpn1 mRNA and protein levels (Figure 5.6 A, G-J). As expected, IRE-independent 
































Figure 5.5 Increased doses of hinokitiol increase uptake into shDMT1 
Caco-2 monolayers, a bimodal transport effect is observed.  
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did not change, and no changes in FPN1 were observed upon the addition of hinokitiol in the 
absence of iron (Figure 5.6 A, L-O). Most interestingly, a reversal of these effects was observed 
with higher concentrations of hinokitiol, even though by radioactive iron we know that the 
uptake of iron into the cells mediated by hinokitiol is steadily increasing (Figure 5.6 A-O). This 
indicates that while the iron within the cells is high the iron response proteins are unable to sense 
it. This points towards a situation where the cell has a lot of iron in it, but that iron is not “free” 
or labile. In the field this is called the chelatable iron pool4.  
 
Figure 5.6 Bimodal effects in hinokitiol treated shDMT1 Caco-2 monolayers. (A) 
Representative Western blot images of proteins involved in iron absorption and regulation after 
treatment with increasing hinokitiol and 25 mM FeCl3. Bimodal effects were observed in protein 
shDMT1 + Hino (µM)
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Figure 5.6 (cont.) levels involved in iron absorption and regulation. (B) Increased ferritin (5’-
IRE) levels (N = 6-21) and (C) increased 55Fe incorporation into immunoprecipitated ferritin was 
observed up to 5 µM hinokitiol. N = 11-15. (D) TfR1 (3’-IRE) levels decrease up to 5 µM 
hinokitiol N = 8. (E and F) As expected, (E) IRP1 levels did not change (N = 14) while (F) 
decreased IRP2 protein levels were observed, consistent with hinokitiol-mediated increases in 
labile iron levels leading to translational regulation of ferritin and TfR1. N = 12. (G and H) 
Consistent with Hif2α-mediated transcriptional regulation of FPN1, (G) decreased FPN1 protein 
(N = 16) and (H) decreased Fpn1 mRNA levels were observed upon hinokitiol treatment up to 5 
µM. N = 9-12. (I and J) Hif1α and Hif2α levels respond to increases in labile iron up to 5 µM 
hinokitiol. N = 4-13. (I) Presumably due to shRNA targeting DMT1, no translational regulation 
of DMT1 was observed up to 5 µM hinokitiol. N = 6. (B-I) These effects were reversed upon 
treatment with higher doses of hinokitiol up to 50 µM, possibly due to competitive chelation of 
labile iron with high hinokitiol doses. (K) IRE-independent protein levels of the iron chaperone 
PCBP1 (N = 6) and (L) Hif2α-independent Fth1 mRNA levels did not change when treated with 
hinokitiol under identical conditions. N = 16. (M and N) No changes were observed in FPN1 
levels treated with hinokitiol in the absence of added iron, supporting the conclusion that the 
changes observed were due to translational and transcriptional responses to dynamic cellular iron 
status. N = 6-8. (A-L) Experiments in shDMT1 Caco-2 monolayers used apical addition of 
hinokitiol (0, 0.5, 1, 3, 5, 10, 25, and 50 µM) in the presence of 25 µM apical FeCl3 for 4 hours 
in the pH=5.5 apical buffer and pH=7.4 basolateral buffer as described previously. (M and N) 
Experiments utilized identical conditions using 500 nM Fe. 
 
 We therefore chose to use calcein green, a fluorescent dye which only detects the labile 
iron within the cytosol and does not take into account the tightly bound iron. Visualization of 
















































































DMSO 5 µM Hino 50 µM Hino
C
Figure 5.7 Despite large influxes of iron into cells with intermediate and high hinokitiol 
concentrations, the labile iron pool shows a bimodal effect. (A) Intermediate 
concentrations of hinokitiol lead to significant calcein green quenching in shDMT1 
monolayers treated with 25 µM FeCl3 after 1 hour, consistent with increased labile iron. This 
effect was reversed at high doses of hinokitiol. Scale bar, 20 mM. (B and C) ImageJ 
quantification of calcein green fluorescence in these monolayers (n = 3 to 6).  
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monolayers with increasing hinokitiol 
led to increased labile iron up to 5 µM 
(Figure 5.7 A-C). Interestingly, further 
increases in hinokitiol concentration 
prevented fluorescence quenching, this 
means that while the total iron in the 
cell is high (Figure 5.7 C), the calcien 
cannot bind it and therefore it is not 
labile and the IREs are not recognizing 
it. One possibility is that the excess 
iron is being bound by ferritin, 
however ferritin protein levels go 
down above 5 µM and 55Fe 
incorporation into ferritin also begins 
to trend downwards, although not 
statistically significantly.  In order 
to determine if the hinokitiol 
concentration within the caco-2 cells 
was increased with increasing concentrations of hinokitiol I turned to tritiated hinokitiol to track 
where the hinokitiol was located during the experiment. I found that as the concentration of 
hinokitiol in the system increased, a disproportionate amount of hinokitiol, was located in the 
intracellular fraction, which makes up ~0.5% of the total volume of the system (Figure 5.8). 
Specifically, in cells treated with 10 uM Hinokitiol ~20% of the total trititated hinokitiol was 
Figure 5.8 Hinokitiol builds up disproportionally 
intracellularly in shDMT1 Caco-2 cells treated 
with >10 µM hinokitiol. Percent of hinokitiol (A) 
apically (B) intracellularly (C) and basolaterally. At 
doses of hinokitiol >10 µM a disproportionate amount 
of hino was thus found to be localized intracellularly 
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found to be in the intracellular fraction (Figure 5.8 B). This data corresponds with the 
fluctuation point we see in the other experiments which occurs in the 10 uM treatment group.  In 
combination, these results lead us to the hypotheis that hinokitiol is competitively chelating and 
sequestering iron in the labile iron pool inside of cells (Figure 5.9).  
 Some future work that is needed in further 
support of this hypothesis is needed. Looking in 
other systems, such as yeast, MELs, and J774 cells 
for intracellular aggregation with tritiated hinokitiol 
would help demonstrate that this is a general 
biophysical behavior of hinokitiol. Additionally 
exchange experiments, similar to the one in Figure 
5.3 D, would be helpful to discover if high 
hinokitiol concentrations cause the iron exchange 
rate to be slower. A slower exchange rate could 
reduce iron assimilation into endogenous proteins 
and regulatory networks causing a lack of iron 
mobilization across the basolateral membrane. All 
together these data have shown that hionkitiol has unique biophysical properties that allow the 
restoration of regulated site- and direction-selective iron transport by harnessing gradients in ron 
transporter defiencent systems. This efficacy is lost at higher concentrations due to hinokitiol 





Figure 5.9 Hypothesized hinokitiol 
intracellular aggregate caused by high 
concentrations of hinokitiol cause 
intracellular iron sequestration.  
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5.5 METHODS    
Materials  
 Wild type (DEY1457) and isogenic fet3Δftr1Δ S. cerevisiae were obtained from D. 
Kosman13. Wild type (YPH499) and isogenic fet3Δarn1-4Δ S. cerevisiae were obtained from C. 
Philpott14. Yeast were maintained on standard YPD media containing 10 g/L yeast extract, 20 
g/L peptone, and 20 g/L dextrose without (liquid media) or with (solid media) 20 g/L agar. 
Unless otherwise indicated, growth-restoration assays in yeast used a low iron SD media 
consisting of 1.91 g/L iron-free YNB-FeCl3 (ForMedium CYN 1201), 0.79 g/L Complete 
Supplement Mixture (Sunrise Science Products 1001-010), 5 g/L ammonium sulfate (Sigma 
A4418), 20 g/L dextrose, 10 µM FeCl3 (Sigma 451649), and 10 µM hinokitiol (β-Thujaplicin, 
Sigma 469521) in 50 mM MES/Tris buffer at pH=7.0 without (liquid media) or with (solid 
media) 20 g/L agar. Dextrose, hinokitiol, and FeCl3 were added after autoclave sterilization from 
a filter-sterilized 40% w/v dextrose solution in water, from a freshly prepared sterile 10 mM 
hinokitiol stock in DMSO, and from a freshly prepared 10 mM FeCl3 stock in sterile water, 
respectively. Non-fermentable growth restoration used the same synthetic medium except for the 
use of 30 g/L glycerol instead of dextrose.  
 Human Caco-2 cells (HTB-37) and mouse macrophages (J774A.1) were obtained from 
ATCC and cultured with DMEM (Gibco 10313-021) containing 10% HI FBS (Gibco 16000-
036), 4 mM glutamine (Lonza BE17-605E), 100 µg/mL PEN-STREP (Lonza DE17-602E), and 
1% MEM NEAA (Fisher 11140-050). Transfected Caco-2 cell lines were maintained on this 
media containing 800 mg/L G418 (Santa Cruz sc-29065B). Friend mouse erythroleukemia cells 
(MEL, DS19 subclone) were obtained from Arthur Skoultchi (Albert Einstein College of 
Medicine, Bronx, NY) and cultured with DMEM containing 10% HI FBS, 2 mM glutamine, 100 
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µg/mL PEN-STREP, and 1% MEM NEAA. Transfected shControl and shDMT1 MEL cell lines 
were maintained on this media containing 1 g/L G418. 
 Caco-2 cells (passage 18-50) were grown in T75 flasks to ≥90% confluency before 
trypsinization with 0.25% trypsin-EDTA (Fisher 25200-056) and passaging at 10:1 dilution in 
Caco-2 media without (wild type) or with G418 (transfected). Monolayers were grown by 
seeding Caco-2 cells (passage 20-50) onto 0.4 µm PET cell culture inserts (Fisher 08-771) in 6-
well companion plates (Fisher 08-771-24) at 2x105 cells/well and allowed to fully differentiate 
for 21-28 days before experiments were performed with changing of media every 3-4 days.  
 MEL cells were grown in suspension in T25 flasks until ~1x106 cells/mL and re-seeding 
into a new T25 flask at 1x105 cells/mL in MEL Complete media with or without G418. Every 
month of culturing, new backstocks of MEL cells were used. 
 J774 cells (passage 20-80) were grown in T25 flasks to ≥90% confluency before scraping 
and re-seeding at 5:1 dilution in J774 Complete media. Media was changed every 1-2 days. 
 
Statistics 
 All data depicts the means or weighted mean ± SEM with a minimum of 3 biological 
replicates unless otherwise noted. Statistical analysis represents P values obtained from student t-
test or one- or two-way analysis of variance (ANOVA) with post-hoc TUKEY test where 







Growth rescue of fet3Δftr1Δ yeast with small molecules in liquid media  
 Growth rescue in yeast was performed similar to previously reported15 using 10 µM 
hinokitiol in low iron SD liquid media containing 10 µM FeCl3 in a 96-well plate unless 
otherwise noted. Wild type and fet3Δftr1Δ controls treated with vehicle (DMSO) were 
performed under identical conditions using the same low iron SD media containing 10 µM FeCl3 
in the absence of hinokitiol. Yeast were grown overnight in YPD media and diluted at an OD600 
of 0.1 in SD media, diluted 10-fold, and incubated at 30 °C with continuous shaking (200 rpm). 
The OD600 was obtained 24-48 hours after inoculation unless otherwise noted.  
 Small molecule dose-response with hinokitiol and C2-deoxy hinokitiol (C2deOHino, see 
synthesis below) was determined by addition of the small molecule (40X stock solution in 
DMSO) to give the indicated final concentrations.  
 
Determination of the pKa of hinokitiol  
 The pKa of hinokitiol was determined by spectrophotometric titration with varying pH. 
Hinokitiol (100 µM) was dissolved in a 0.1 M KCl solution in H2O and acidified to pH = 3.0 
(using 0.1 M HCl). The UV-Vis spectrum was repeatedly obtained upon sequential titration of 
0.1 M KOH to obtain a range of pHs (3.0, 3.4, 3.9, 4.2, 4.6, 4.9, 6.0, 6.4, 7.0, 7.2, 7.6, 8.4, 9.3, 
9.7, 10.4, 10.9, 11.7, 12.0). A clear isobestic point was observed at 365 nm, and a new λmax was 
observed with decreasing pH at 387 nm. The pKa was then determined via plotting the Abs387 / 
Abs240 vs. pH and logistic fitting on OriginPro (R2 = 0.996) to calculate the point of inflection 





Determination of small molecule iron binding  
 Small molecule iron (III) binding was determined by UV-Vis spectroscopy of small 
molecules (30 µM) before and after addition of FeCl3 (10 µM) or iron (III) citrate (10 µM, Sigma 
F3388) in 10 mM MES/Tris buffer at pH=7.0. Iron (II) binding was determined by UV-Vis 
spectroscopy of small molecules (30 µM) and FeCl2 (10 µM) in a 25 mM MES/Tris buffer at 
pH=7.0 containing 62.5 mM sodium ascorbate.  
 
Determination of iron (II) and iron (III) binding affinity with small molecules  
 The association constants of hinokitiol, deferiprone, tropolone, maltol, and/or EDTA with 
iron (II) or iron (III) were determined through competition studies similar to previously 
reported5. Specifically, the association constant for iron (II) was determined by a ferrozine 
competition assay (KA of ferrozine = 3.65x1015)6 FeCl2 (25 µM) was pre-mixed with ferrozine 
(75 µM) in a 25 mM MES/Tris buffer at pH=7.0 containing 62.5 mM sodium ascorbate. Then 
increasing concentrations of small molecule (from 40X stocks in DMSO) were added to the 
indicated final concentrations. The solutions were allowed to equilibrate for 24 hours before 
reading of the absorbance at 562 nm. The association constants of hinokitiol, tropolone, and 
deferiprone for iron (III) was determined by an EDTA (KA = 1.7x1024) competition assay5, and a 
citrate (KA = 1x1017) competition assay for maltol7. Each chelator was mixed with FeCl3 in a 3:1 
ratio in 50 mM MES/Tris buffer at pH=7.0 containing 0.1 M KCl to form the corresponding iron 
complex. The λmax of the peak corresponding to the 3:1 chelator:iron complex was determined 
(~400-500 nm) for each complex. Then this Fe(chelator)3 stock was added to a solution 
containing increasing concentrations of EDTA or citrate in 50 mM MES/Tris buffer at pH=7.0 
containing 0.1 M KCl to give the indicated final concentrations of chelator (75 µM), FeCl3 (25 
µM), and the competitive chelator. The system was allowed to equilibrate overnight, and the 
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absorbance corresponding to the Fe(chelator)3 complex was determined. The EC50 values for 
each chelator were calculated by a nonlinear curve fit (Hill1) on OriginPro by plotting the 
absorbance vs. concentration of titrant, and the KA for each complex was determined from the 
equation: KA, ligand = (KA, competitor * [EC50]) / [ligand] where the ligand is the molecule originally 
bound to iron, and the competitor is the competing chelator. 
 
Removal of 55Fe from iron-binding proteins with hinokitiol 
 
 The capacity for hinokitiol to remove iron from transferrin was determined through a 55Fe 
assay adapted from Cerami and coworkers8. 55Fe was loaded onto transferrin (Tf) similar to 
previously described in PBS buffer9. Increasing hinokitiol doses (from 1000X stocks in DMSO) 
were added to a solution of 55Fe2Tf (1 nM) in PBS buffer to give the final indicated 
concentrations. The solution was incubated at 37 °C for 3 hours. After incubation, any 55Fe 
bound to hinokitiol was isolated by extraction of iron:hinokitiol complexes with EtOAc. The 
radioactive levels in the organic layer were determined after dilution in scintillation cocktail. No 
extraction of 55Fe was observed in the absence of hinokitiol, and transferrin was not denatured 
from the extraction process as determined by UV-Vis spectroscopy of holo-transferrin before and 
after EtOAc extraction in PBS buffer.  
 Ferritin was loaded with 55Fe by incubation of wild type Caco-2 monolayers and isolation 
of ferritin through immunoprecipitation as described below. The immunoprecipitated ferritin was 
diluted to 2.5 ng ferritin/mL (determined by ELISA as described below) in 50 mM MES/Tris 
buffer at pH=7.0, and increasing concentrations of hinokitiol were added (from 1000X stock in 
DMSO) to give the final indicated concentrations. The suspension was mixed at room 
temperature for 2 hours. After incubation, repeated centrifugations and rinses with PBS were 
	
	 130	
performed to remove any 55Fe not bound to ferritin, and the radioactive levels remaining in the 
agar pellet were determined after dilution in scintillation cocktail and liquid scintillation 
counting.  
 
Determination of hinokitiol binding selectivity by ICP-MS  
 The binding selectivity for hinokitiol with multiple divalent metals was determined 
similar to previously described10. Specifically, a 2 mM solution of hinokitiol in 10 mM MES/Tris 
buffer in 1:1 H2O:MeOH at pH=7.0 was mixed in equal volume with a solution containing 2 mM 
FeCl2, 2 mM MnCl2, 2 mM CoCl2, 2 mM NiCl2, 2 mM ZnCl2, and 2 mM CuCl2 in a 10 mM 
MES/Tris buffer in 1:1 H2O:MeOH at pH=7.0 to give a final concentration of 1 mM for each 
divalent metal and hinokitiol. The colored solution was allowed to incubate for 4 hours at room 
temperature. The solution was diluted in buffer, and extracted (x3) using 1:1 Hexanes:Ethyl 
Acetate. The organic layer was collected, dried by MgSO4, and filtered. The solvent was 
removed in vacuo, digested with 70% HNO3, and metal content was determined by ICP-MS 
analysis through the University of Illinois SCS Microanalysis Facility.  
 Control experiments were performed similar to those described above but in the absence 
of hinokitiol. No metal was detected in the organic layer by ICP-MS. Control experiments were 
also performed similar to those described above but using 60 mM hinokitiol. Metal content after 
extraction was compared to the initial metal content in the aqueous solution before extraction, 
and it was determined that the metal:hinokitiol complexes are extracted into the organic layer.  
Determination of metal selectivity in yeast  
 Hinokitiol-mediated changes in intracellular metal levels were determined using growth 
rescue conditions adapted from he Fe uptake study.. Specifically, wild type and fet3Δftr1Δ yeast 
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were grown in YPD media overnight, rinsed, and incubated in SD media without FeCl3 at 30 °C 
for 3 hours. Yeast were then resuspended at an OD600 = 0.50 in SD media (50 mM MES/Tris, 
pH=7.0) containing 100 µM FeCl3 and either DMSO vehicle or 10 µM hinokitiol. After 2.5 
hours of incubation, cells were centrifuged at 5 °C, rinsed twice with cold 10 mM EDTA in 50 
mM Tris/HCl buffer (pH = 6.5), and once with cold metal-free water. Cells were then lyophilized 
for 48 hours. The lyophilized cells were digested with a 5:1 mixture of HNO3:HCl and then 
subjected to an automated sequential microwave digestion in a CEM Discover SP-D microwave 
digester. The resulting clear solution was diluted in metal-free water, and elemental analysis was 
performed by ICP-MS through the University of Illinois SCS Microanalysis Facility using a 
Perkin Elmer DRC-e instrument.  
 
Exchangeability of ferric iron bound to hinokitiol 
 The reversible exchange of ferric iron bound to hinokitiol was determined similar to 
previously described11. Non-radioactive FeCl3 (100 nM from a 1000X stock, referred to as 56Fe) 
was added to hinokitiol (100 nM from a 1000X stock) in 10 mM MES/Tris buffer at pH=7.0. 
The solution was equilibrated for 1 hour at 37 °C, and then an equal amount of 55FeCl3 (100 nM) 
was added. The solution was incubated at 37 °C, and at the indicated time points an aliquot was 
taken and added to water. The iron-hinokitiol complex was immediately separated from unbound 
iron through extraction with ethyl acetate and the radioactive counts were determined by 
scintillation counting. Less than 2% of iron was found in the ethyl acetate layer in the absence of 
hinokitiol. The percent equilibrium was then determined by normalizing the radioactive counts 




Western blotting conditions  
 Caco-2 monolayers, differentiated MEL cells, or J774 cells underwent treatment as 
described in rescue experiments before lysis with RIPA buffer (Thermo 89901) containing 
protease inhibitors (Thermo 88266). Protein concentrations were determined by a BCA kit 
(Thermo 23225) and diluted to 2 mg/mL in the same RIPA buffer. Relative protein levels were 
then determined through western blotting of 10 or 20 µg of protein lysate blocking for 2 hours at 
room temperature with 5% BSA and using primary antibodies consisting of either human anti-
DMT1 (1:3,000 dilution, Santa Cruz sc-30120), mouse anti-DMT1 (1:1,000 dilution, Santa Cruz 
sc-166884), human anti-FTL1 (1:1,000 dilution, Santa Cruz sc-74513), human anti-FPN1 HRP 
conjugate (1:10,000 dilution, Novus Biologicals NBP1-21502H), mouse anti-globin α HRP 
conjugate (not heated at 100 °C, 1:10,000 dilution, Lifespan Biosciences LS-C212172), human 
anti-TfR1 HRP conjugate (1:10,000 dilution, Abcam ab10250), human anti-IRP1 (1:1,000 
dilution, Santa Cruz sc-14216), human anti-IRP2 (1:1,000 dilution, Santa Cruz sc-33682), human 
anti-Hif1α HRP conjugate (1:1,000 dilution, Novus Biologicals NB100-105H), human anti-
Hif2α HRP conjugate (1:1,000 dilution, Novus Biologicals NB100-122H), human anti-PCBP1 
(1:1,000 dilution, Santa Cruz sc-393076), or human anti-actin HRP conjugate (1:10,000 dilution, 
Cell Signaling 5125S) in 5% BSA overnight at 5 °C before rinsing thoroughly with TBST and 
incubation (if non-HRP conjugated) with secondary antibody consisting of either goat anti-rabbit 
IgG HRP conjugate (1:5,000 dilution – DMT1, Cell Signaling 7074, in 5% milk), goat anti-
mouse IgG1 HRP conjugate (1:1,000 dilution – PCBP1, 1:5,000 dilution – IRP2, 1:3,000 dilution 
– DMT1, Santa Cruz sc-2060, in 5% BSA), donkey anti-goat IgG HRP conjugate (1:1,000 
dilution – IRP1, Santa Cruz sc-2020, in 5% BSA), or goat anti-mouse IgG2a HRP conjugate 
(1:10,000 dilution – FTL1, Santa Cruz sc-2061, in 5% BSA) at room temperature for two hours. 
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Blots were thoroughly rinsed with TBST and imaged after addition of Femto Chemluminescence 
solution according to manufacturer instructions (Thermo Fisher 34095).  
 
Determination of ferritin levels by ELISA  
 Absolute ferritin protein levels in shControl and shDMT1 Caco-2 monolayer lysates were 
determined using a commercial sandwich ELISA kit (Abcam ab108837) according to 
manufacturer instructions. 
 
55Fe uptake and transport in differentiated Caco-2 monolayers  
 Media from differentiated Caco-2 monolayers (P25-50, 21-28 days post seeding) grown 
on PET inserts in 6-well plates was aspirated, and monolayers were rinsed with PBS. 2 mL of 
basolateral fluid (serum-free DMEM at pH = 7.4 in 10 mM HEPES buffer) was added to the 
basolateral side, and 1 mL of apical fluid (serum-free DMEM at pH = 5.5 in 10 mM MES buffer) 
containing 200 nM 55FeCl3 and 25 µM FeCl3 and either DMSO vehicle, or hinokitiol at the 
indicated concentrations was added to the apical side via addition on the wall of the membrane 
insert without disrupting the cell monolayer. The monolayers were then incubated for four hours 
at 37 °C unless otherwise noted. A 100 µL aliquot of the basolateral fluid was removed, diluted 
in scintillation cocktail, and radioactivity was determined on a liquid scintillation counter to 
quantify relative amounts of 55Fe transport. To determine intracellular 55Fe, the remaining 
basolateral and apical fluid was removed, and the monolayer was rinsed with PBS (x2). The cells 
were then lysed with 500 µL of 200 mM NaOH with nutator mixing overnight, and radioactivity 
was determined on a liquid scintillation counter after diluting the cell lysate in scintillation 
cocktail. All values were normalized to shControl monolayers unless otherwise noted. Absolute 
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iron levels were determined through calibration of 55Fe radioactivity levels with known standards 
and average mg of protein per membrane was determined by protein lysis with RIPA buffer 
containing protease inhibitors and quantified through a BCA kit according to manufacturer 
instructions.  
 
55Fe immunoprecipitation of ferritin in Caco-2 monolayers 
 Immunoprecipitation of ferritin was performed using human anti-FTL1 (Santa Cruz sc-
74513) and Protein G PLUS-Agarose beads (Santa Cruz sc-2002). Cell lysate was obtained from 
shControl and shDMT1 Caco-2 monolayers after apical treatment with DMSO or hinokitiol (0, 
0.5, 1, 3, 5, 10, 25, or 50 µM) and FeCl3 (200 nM of 55Fe for and 25 µM of 20:1 56Fe:55Fe) for 
four hours as described above. Cell lysate was incubated with primary antibody (1:100 dilution) 
at room temperature for 1 hour, then with the secondary antibody (1:10 dilution) at room 
temperature for 1 hour with constant mixing. Repeated centrifugations and PBS rinses were 
performed, and the radioactive levels in the agarose pellet were determined by dilution in 
scintillation fluid. 
 
Temporal imaging of cytosolic iron with calcein green in Caco-2 monolayers  
 Temporal live cell imaging of labile iron levels in shDMT1 Caco-2 monolayers was 
performed after staining of Caco-2 monolayers with calcein green-AM (5 µM) in the apical and 
basolateral liquid for 30 minutes in pH=7.4 DMEM. After rinsing with PBS (x2 apically and 
basolaterally), monolayers were treated similar to Caco-2 transport experiments with a pH=7.4 
HEPES buffer in DMEM (basolateral) and an apical fluid (pH=5.5 MES buffer in DMEM) 
containing 25 µM FeCl3 and either 0, 0.5, 1, 3, 5, 10, 25, or 50 µM hinokitiol (from 1000x stocks 
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in DMSO). Calcein green fluorescence was obtained at t = 0 min and t = 60 min, and the 
fluorescence in each image was quantified by ImageJ analysis. 
 
Localization of Hinokitiol in the Caco-2 monolayer system using tritiated hinokitiol 
 Media from differentiated Caco-2 monolayers (P25-50, 21-28 days post seeding) grown 
on PET inserts in 6-well plates was aspirated, and monolayers were rinsed with PBS. 2 mL of 
basolateral fluid (serum-free DMEM at pH = 7.4 in 10 mM HEPES buffer) was added to the 
basolateral side, and 1 mL of apical fluid (serum-free DMEM at pH = 5.5 in 10 mM MES buffer) 
containing 25 µM FeCl3, 4.6 nM tritiated hinokitiol and either DMSO vehicle, or indicated 
concentration hinokitiol from a 1000X stock in DMSO was added to the apical side via addition 
on the wall of the membrane insert without disrupting the cell monolayer. The monolayers were 
then incubated for four hours at 37 °C. A 100 µL aliquot of the apical and basolateral fluid was 
removed, diluted in scintillation cocktail, and radioactivity was determined on a liquid 
scintillation counter to quantify relative amounts of tritiated hinokitiol. To determine intracellular 
tritiated hinokitiol, the remaining basolateral and apical fluid was removed, and the monolayer 
was rinsed with PBS (x2). The cells were then lysed with 500 µL of 200 mM NaOH with nutator 
mixing overnight, and radioactivity was determined on a liquid scintillation counter after diluting 
the cell lysate in scintillation cocktail. All values are expressed as percent of the total tritiated 
hinokitiol in the system.  
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SUMMARY AND OUTLOOK 
	
 
These findings demonstrate that the small molecul hinokitiol can restore mobilization of 
iron into, within and out of cells deficient in many different iron transporters. Hinokitiol is the 
first small moecule, molecular prothetic to restore physiology downsttream of a missing iron 
transporter in a whole animal. The mobilization of iron by hinokitiol seems to be regulated via an 
interface of hinokitiol with the natural system. This is made possible by iron gradients which 
accumulate upstream of the missing iron transporters. It is intriguing to consider whether other 
ion transporter deficiencies create similar ion gradients, potentially making this a generalizable 
strategy to develop new therapies for diseases caused by missing ion transporters such as Cystic 
Fibrosis, Barter’s syndrome, and Liddle syndrome. Therefore these studies provide a conceptual 
framework and proof-of-concept demonstration to support the pursuit of small molecule 
surrogates for missing or dysfunctional iron-transport proteins that underlie many human 
diseases.  
The disorders outline herein are very rare with a few patients world wide. However, it has 
recently been recognized that acquired, rather than genetic germline, deficiencies of FPN1 
underlie the anemia of chronic inflammation that frequently occurs in patients suffering from 
many common diseases, including rheumatoid arthritis, systemic lupus erythematosus, and 
inflammatory bowel disease1–3. Genetic or induced deficiencies of FPN1 underlie many other 
diseases, including hemochromatosis type IV (Ferroportin disease)4, mentioned in this thesis, as 
well as  iron-refractory iron deficiency anemia (IRIDA)5 and Anemia of Inflammation (AI)3,6–8. 
AI decreases the quality of life in >10 million patients suffering from autoimmune disorders 
including rheumatoid arthritis, celiac disease, systemic lupus erythematosus, inflammatory bowel 
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disease, and ulcerative colitis.8 Moreover, ~50,000 children with juvenile idiopathic arthritis 
suffer from anemia that leads to decreased energy, growth, and cognition during the critical early 
years of their development.9–11 Current therapies fail to address the common underlying defect 
that duodenal enterocytes and reticuloendothelial macrophages are unable to mobilize iron across 
specific membranes. Effectively addressing AI typically requires intravenous iron therapy and/or 
trying to eliminate the source of inflammation, the former can lead to iron overload in select 
tissues such as the liver and the latter is, in many cases, challenging to achieve.3,12,13   
Hinokitiol has the potential to treat disorders of aquired ferroportin deficiency due to its 
ability to autonomously perform transmembrane iron transport and leverage iron gradients which 
accumulate upstream of deficient iron transporters to restore site- and direction- selective iron 
transport and thus physiology. Further, this approach may have potential in promoting the rapid 
excretion of excess iron that builds up in tissues (e.g. liver or brain) in many diverse iron 
overload disorders such as hereditary hemochromatosis14–17. Because networks of active and 
passive ion-transport proteins similarly underlie the directional movement of many other ions in 
most living systems, including humans, these findings may also have even broader scientific and 
therapeutic implications for treating human diseases which are currently untreatable.  
This project has started a world wide network of collaborators all rallying around 
hinokitiol as an interesting biological probe and potential therapuitc. I look forward to watching  
and potentially advising future studies and colaborators as hinokitiol is developed into a 







1. Poggiali, E., Migone De Amicis, M. & Motta, I. Anemia of chronic disease: A unique 
defect of iron recycling for many different chronic diseases. Eur. J. Intern. Med. 25, 12–
17 (2014). 
2. Basseri, R. J. et al. Hepcidin is a key mediator of anemia of inflammation in Crohn’s 
disease. J. Crohn’s Colitis 7, 1–2 (2013). 
3. Gangat, N. & Wolanskyj, A. P. Anemia of chronic disease. Semin. Hematol. 50, 232–238 
(2013). 
4. Pietrangelo, A. The ferroportin disease. Blood Cells, Mol. Dis. 32, 131–138 (2004). 
5. Finberg, K. E. et al. Mutations in TMPRSS6 cause iron-refractory iron deficiency anemia 
(IRIDA). Nat. Genet. 40, 569–571 (2008). 
6. Ganz, T. & Nemeth, E. Iron Sequestration and Anemia of Inflammation. Semin. Hematol. 
46, 387–393 (2009). 
7. Rivera, S. & Ganz, T. Animal Models of Anemia of Inflammation. Semin. Hematol. 46, 
351–357 (2009). 
8. Wessling-Resnick, M. Iron homeostasis and the inflammatory response. Annu. Rev. Nutr. 
30, 105–22 (2010). 
9. Ravelli, A. & Martini, A. Juvenile idiopathic arthritis. Lancet 369, 767–778 (2007). 
10. Cazzola, M. et al. Defective iron supply for erythropoiesis and adequate endogenous 
erythropoietin production in the anemia associated with systemic-onset juvenile chronic 
arthritis. Blood 87, 4824–4830 (1996). 
11. Egorov, A. et al. Anemia in children with JIA: is it really driven by hepcidin level, or by a 
set of factors of a chronic disease. Pediatr. Rheumatol. 12, P187 (2014). 
	
	 140	
12. Sun, C. C., Vaja, V., Babitt, J. L. & Lin, H. Y. Targeting the hepcidin-ferroportin axis to 
develop new treatment strategies for anemia of chronic disease and anemia of 
inflammation. Am. J. Hematol. 87, 392–400 (2012). 
13. Ganz, T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of 
inflammation. Blood 102, 783–788 (2003). 
14. Pietrangelo, A. Hereditary Hemochromatosis — A New Look at an Old Disease. N. Engl. 
J. Med. 350, 2383–2397 (2004). 
15. Anderson, G. J. Ironing Out Disease: Inherited Disorders of Iron Homeostasis. IUBMB 
Life (International Union Biochem. Mol. Biol. Life) 51, 11–17 (2001). 
16. Brissot, P. et al. Current approach to hemochromatosis. Blood Rev. 22, 195–210 (2008). 
17. Montosi, G. et al. Wild-type HFE protein normalizes transferrin iron accumulation in 
macrophages from subjects with hereditary hemochromatosis. Blood 96, 1125–1129 
(2000). 
	
